<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cts70136" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Sci</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1752-8062</journal-id><journal-id journal-id-type="publisher-id">CTS</journal-id><journal-title-group><journal-title>Clinical and Translational Science</journal-title></journal-title-group><issn pub-type="ppub">1752-8054</issn><issn pub-type="epub">1752-8062</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891427</article-id><article-id pub-id-type="pmc">PMC11786019</article-id><article-id pub-id-type="doi">10.1111/cts.70136</article-id><article-id pub-id-type="publisher-id">CTS70136</article-id><article-id pub-id-type="other">CTS-2024-0573-T</article-id><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Role of Candidate Polymorphisms in Drug Transporter Genes on High&#x02010;Dose Methotrexate in the Consolidation Phase of the AIEOP&#x02010;BFM ALL 2009 Protocol</article-title></title-group><contrib-group><contrib id="cts70136-cr-0001" contrib-type="author"><name><surname>Braidotti</surname><given-names>Stefania</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7463-5776</contrib-id><xref rid="cts70136-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70136-cr-0002" contrib-type="author"><name><surname>Zudeh</surname><given-names>Giulia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6168-5662</contrib-id><xref rid="cts70136-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cts70136-cr-0003" contrib-type="author" corresp="yes"><name><surname>Franca</surname><given-names>Raffaella</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8569-2023</contrib-id><xref rid="cts70136-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>rfranca@units.it</email></address></contrib><contrib id="cts70136-cr-0004" contrib-type="author"><name><surname>Kiren</surname><given-names>Valentina</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5190-3785</contrib-id><xref rid="cts70136-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70136-cr-0005" contrib-type="author"><name><surname>Colombini</surname><given-names>Antonella</given-names></name><xref rid="cts70136-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cts70136-cr-0006" contrib-type="author"><name><surname>Bettini</surname><given-names>Laura Rachele</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0280-1704</contrib-id><xref rid="cts70136-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cts70136-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cts70136-cr-0007" contrib-type="author"><name><surname>Brivio</surname><given-names>Erica</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5285-1702</contrib-id><xref rid="cts70136-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cts70136-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cts70136-cr-0008" contrib-type="author"><name><surname>Locatelli</surname><given-names>Franco</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7976-3654</contrib-id><xref rid="cts70136-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="cts70136-cr-0009" contrib-type="author"><name><surname>Vinti</surname><given-names>Luciana</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2803-992X</contrib-id><xref rid="cts70136-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="cts70136-cr-0010" contrib-type="author"><name><surname>Bertorello</surname><given-names>Nicoletta</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0371-540X</contrib-id><xref rid="cts70136-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="cts70136-cr-0011" contrib-type="author"><name><surname>Fagioli</surname><given-names>Franca</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9257-900X</contrib-id><xref rid="cts70136-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="cts70136-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="cts70136-cr-0012" contrib-type="author"><name><surname>Silvestri</surname><given-names>Daniela</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0830-1604</contrib-id><xref rid="cts70136-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="cts70136-cr-0013" contrib-type="author"><name><surname>Valsecchi</surname><given-names>Maria Grazia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5574-3504</contrib-id><xref rid="cts70136-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="cts70136-cr-0014" contrib-type="author"><name><surname>Decorti</surname><given-names>Giuliana</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9714-6246</contrib-id><xref rid="cts70136-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cts70136-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cts70136-cr-0015" contrib-type="author"><name><surname>Stocco</surname><given-names>Gabriele</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0964-5879</contrib-id><xref rid="cts70136-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cts70136-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cts70136-cr-0016" contrib-type="author"><name><surname>Rabusin</surname><given-names>Marco</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5555-5538</contrib-id><xref rid="cts70136-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cts70136-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>Institute for Maternal and Child Health &#x02010; IRCCS Burlo Garofolo</institution>
<city>Trieste</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Translational and Advanced Diagnostics</named-content>
<institution>Institute for Maternal and Child Health &#x02010; IRCCS Burlo Garofolo</institution>
<city>Trieste</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medical, Surgical and Health Sciences</named-content>
<institution>University of Trieste</institution>
<city>Trieste</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Department of Pediatrics, IRCCS San Gerardo dei Tintori</institution>
<city>Monza</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>University of Milano&#x02010;Bicocca</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatric Oncology</named-content>
<institution>Erasmus MC&#x02010;Sophia Children's Hospital Rotterdam</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="cts70136-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Princess M&#x000e1;xima Center for Pediatric Oncology</institution>
<city>Utrecht</city>
<country country="NL">The Netherlands</country>
</aff><aff id="cts70136-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Hematology, Oncology and of Cell and Gene Therapy</named-content>
<institution>IRCCS Ospedale Pediatrico Bambino Ges&#x000fa;, Catholic University of the Sacred Heart</institution>
<city>Rome</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Paediatric Onco&#x02010;Haematology Department</named-content>
<institution>Regina Margherita Children's Hospital</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Public Health and Pediatrics</named-content>
<institution>University of Turin</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff id="cts70136-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Bicocca Centre of Bioinformatics, Biostatistics and Bioimaging, School of Medicine and Surgery</named-content>
<institution>University of Milano Bicocca</institution>
<city>Milano</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Raffaella Franca (<email>rfranca@units.it</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue seq="90">2</issue><issue-id pub-id-type="doi">10.1111/cts.v18.2</issue-id><elocation-id>e70136</elocation-id><history>
<date date-type="rev-recd"><day>27</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>29</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>03</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 ASCPT.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Clinical and Translational Science</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CTS-18-e70136.pdf"/><abstract><title>ABSTRACT</title><p>High&#x02010;dose methotrexate (HD&#x02010;MTX) infusions are commonly used to consolidate remission in children with acute lymphoblastic leukemia (ALL). We investigate the potential role of candidate polymorphisms in <italic toggle="no">SLCO1B1</italic> (rs4149056 and rs2306283), <italic toggle="no">ABCB1</italic> (rs1045642), <italic toggle="no">ABCC2</italic> (rs717620), <italic toggle="no">ABCC3</italic> (rs9895420), and <italic toggle="no">ABCC4</italic> (rs7317112) drug transporters genes on HD&#x02010;MTX pharmacokinetics and patients' outcome (meant both as relapse and drug&#x02010;related toxicities) in an Italian cohort of 204 ALL pediatric patients treated according to the AIEOP&#x02010;BFM ALL 2009 protocol. TaqMan SNP genotyping assays determined patient's genotypes. Measurements of HD&#x02010;MTX plasma concentration were available for 814 HD&#x02010;MTX courses in 204 patients; MTX clearance was estimated by a two&#x02010;compartmental linear pharmacokinetic model with first&#x02010;order elimination and a Bayesian approach, via ADAPT. Independent contributions of age and <italic toggle="no">ABCC4</italic> SNP rs7317112 (A&#x0003e;G, intronic) on MTX clearance were detected in a multivariate analysis (<italic toggle="no">p</italic>&#x02009;=&#x02009;1.57 &#x000d7;&#x02009;10<sup>&#x02212;8</sup> and <italic toggle="no">p</italic>&#x02009;=&#x02009;2.06 &#x000d7;&#x02009;10<sup>&#x02212;5</sup>, respectively), suggesting a delayed elimination of the drug in older patients and an accelerated one in carriers of the variant GG genotype. After multiple corrections, the association between <italic toggle="no">ABCC2</italic> SNP rs717620 (&#x02212;24 C&#x0003e;T) and severe hematological toxicity was found (<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.005). Moreover, <italic toggle="no">SLCO1B1</italic> SNP rs4149056 (c.521T&#x0003e;C, p.V174A) affected patients' outcomes: carriers of the variant C allele presented a reduced risk of relapse compared to wild&#x02010;type TT (hazard risk: 0.27, 95% confidence interval [CI]: 0.08&#x02013;0.90, <italic toggle="no">p</italic>&#x02009;=&#x02009;0.037). Taken together, these data highlighted the importance of variants in drug transporters genes on HD&#x02010;MTX disposition in the AIEOP&#x02010;BFM ALL 2009 protocol consolidation phase, and their putative role as predictive markers of outcome.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cts70136-kwd-0001">drug transporters</kwd><kwd id="cts70136-kwd-0002">high&#x02010;dose methotrexate pharmacokinetics</kwd><kwd id="cts70136-kwd-0003">pediatric acute lymphoblastic leukemia</kwd><kwd id="cts70136-kwd-0004">pharmacogenetics</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="14"/><word-count count="8800"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:01.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cts70136-ntgp-0001"><fn fn-type="equal" id="cts70136-note-0001"><p>Stefania Braidotti and Giulia Zudeh contributed equally to this work.</p></fn><fn fn-type="funding" id="cts70136-note-0002"><p>
<bold>Funding:</bold> This work was supported by the Italian Ministry of Health, through the contribution given to the Institute for Maternal and Child Health IRCCS Burlo Garofolo&#x02010; Trieste, Italy.</p></fn></fn-group></notes></front><body id="cts70136-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="cts70136-blkfxd-0001"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="cts70136-list-0001"><list-item id="cts70136-li-0001"><p>What is the current knowledge on the topic?
<list list-type="simple" id="cts70136-list-0002"><list-item id="cts70136-li-0002"><label>&#x025cb;</label><p>High&#x02010;dose methotrexate (HD&#x02010;MTX) is widely used to consolidate remission in pediatric acute lymphoblastic leukemia (ALL). Single nucleotide polymorphisms (SNPs) in drug transporter genes may affect the pharmacokinetics and toxicity of HD&#x02010;MTX and thus the clinical outcome.</p></list-item></list>
</p></list-item><list-item id="cts70136-li-0003"><p>What question did this study address?
<list list-type="simple" id="cts70136-list-0003"><list-item id="cts70136-li-0004"><label>&#x025cb;</label><p>This study investigated the role of candidate SNPs in drug transporter genes (i.e., <italic toggle="yes">SLCO1B1</italic> rs4149056 and rs2306283, <italic toggle="yes">ABCB1</italic> rs1045642, <italic toggle="yes">ABCC2</italic> rs717620, <italic toggle="yes">ABCC3</italic> rs9895420, and <italic toggle="yes">ABCC4</italic> rs7317112) and/or of HD&#x02010;MTX pharmacokinetics on patients' outcome for the first time in an Italian cohort of ALL pediatric patients treated according to the AIEOP&#x02010;BFM ALL 2009 protocol.</p></list-item></list>
</p></list-item><list-item id="cts70136-li-0005"><p>What does this study add to our knowledge?
<list list-type="simple" id="cts70136-list-0004"><list-item id="cts70136-li-0006"><label>&#x025cb;</label><p>This study provided evidence that genetic variants in drug transporter genes significantly affect HD&#x02010;MTX pharmacokinetics and patient outcomes, highlighting their putative role as predictive markers of outcome in the AIEOP&#x02010;BFM ALL 2009 protocol consolidation phase:
<list list-type="bullet" id="cts70136-list-0005"><list-item id="cts70136-li-0007"><p>
<italic toggle="yes">ABCC4</italic> SNP (rs7317112): Carriers of the variant GG genotype showed accelerated MTX clearance;</p></list-item><list-item id="cts70136-li-0008"><p>
<italic toggle="yes">ABCC2</italic> SNP (rs717620): Carriers of the T&#x02010;variant allele showed an increased risk of drug&#x02010;related adverse effects, in particular of hematological toxicities;</p></list-item><list-item id="cts70136-li-0009"><p>
<italic toggle="yes">SLCO1B1</italic> SNP (rs4149056): Carriers of the C&#x02010;variant allele showed lower risk of relapse.</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item id="cts70136-li-0010"><p>How might this change clinical pharmacology or translational science?
<list list-type="simple" id="cts70136-list-0006"><list-item id="cts70136-li-0011"><label>&#x025cb;</label><p>Our findings emphasize the importance of genetic evaluation for drug transporter polymorphisms in pediatric ALL patients undergoing HD&#x02010;MTX treatment in the therapeutic context of the AIEOP&#x02010;BFM consolidation phase. Identifying patients with significant genetic variants can help personalize treatments, potentially improving therapeutic outcomes and reducing drug&#x02010;related toxicities. This approach can lead to more precise dosing strategies based on individual genetic profiles, advancing the field of pharmacogenomics in pediatric oncohematology and improving patient care.</p></list-item></list>
</p></list-item></list>
</p></boxed-text>
</p><sec id="cts70136-sec-0003"><label>1</label><title>Introduction</title><p>Acute lymphoblastic leukemia (ALL) is one of the most frequent pediatric malignant conditions and represents approximately 80% of leukemia cases occurring in childhood [<xref rid="cts70136-bib-0001" ref-type="bibr">1</xref>]. ALL is treated according to long&#x02010;lasting (~2&#x02009;years) polychemotherapeutic protocols, organized in different phases to induce, consolidate, and maintain remission. The most intense treatment is given within the first 4&#x02013;6&#x02009;months after diagnosis to eradicate leukemic cells, whereas a prolonged mild myelosuppression is required afterward to achieve a sustained event&#x02010;free survival [<xref rid="cts70136-bib-0002" ref-type="bibr">2</xref>].</p><p>Methotrexate (MTX) is a cornerstone drug in ALL therapy, widely used across all therapeutic phases. During induction, the intrathecal administration of MTX is common for central nervous system treatment and prophylaxis, whereas its systemic exposure is recommended once remission is achieved. In particular, high&#x02010;doses MTX (HD&#x02010;MTX, i.e., dose greater than 500&#x02009;mg/m<sup>2</sup>) are intravenously administered to target remaining leukemic blasts in consolidation, whereas low doses of MTX (e.g., 20&#x02009;mg/m<sup>2</sup>) are weekly administered orally in maintenance to keep patients in immunosuppression [<xref rid="cts70136-bib-0002" ref-type="bibr">2</xref>, <xref rid="cts70136-bib-0003" ref-type="bibr">3</xref>]. Being hydrophilic, MTX crosses the biological barriers poorly and through active transport systems. It enters cells by influx folate carriers, such as the well&#x02010;characterized SLC19A1 in enterocytes and SLCO1B1 in hepatocytes; ABC efflux transporters mediate cellular elimination [<xref rid="cts70136-bib-0004" ref-type="bibr">4</xref>, <xref rid="cts70136-bib-0005" ref-type="bibr">5</xref>]. In hepatocytes, most of MTX reenters the blood circulation by ABCC3 (also known as multidrug resistance&#x02010;associated protein, MRP3) and ABCC4 (MRP4), and only a small portion is excreted into the bile ducts via the apical/canalicular ABCC2 (MRP2) and ABCB1 (also known as P&#x02010;glycoprotein or multidrug resistance protein 1, MDR1) [<xref rid="cts70136-bib-0006" ref-type="bibr">6</xref>]. ABCB1 is a ubiquitously expressed pump, and also mediates the active secretion of MTX into urinary filtrate in the proximal tubular cells. ABCC2 and ABCC4 are also located in the apical membrane of the renal epithelial cells, contributing, in this way, to lower body drug exposure; in contrast, ABCC3 is basolateral located in the proximal tubule (Figure&#x000a0;<xref rid="cts70136-fig-0001" ref-type="fig">1A</xref>) [<xref rid="cts70136-bib-0007" ref-type="bibr">7</xref>, <xref rid="cts70136-bib-0008" ref-type="bibr">8</xref>]. Once in the cells, MTX is converted into polyglutamates (MTXPGs) that are retained in cells for a prolonged period and act as antimetabolites interfering with the folate pathway in the dividing cells (Figure&#x000a0;<xref rid="cts70136-fig-0001" ref-type="fig">1B</xref>). Overall, MTXPGs induce the depletion of reduced folates and compromise de novo purine and thymidine synthesis, which are paramount for the survival of leukemic stem cells. These antiproliferative effects are mainly observed for HD&#x02010;MTX; the immunosuppressant effects achieved at low doses MTX are less characterized, likely involving other cellular mechanisms than the folate cycle imbalance [<xref rid="cts70136-bib-0009" ref-type="bibr">9</xref>].</p><fig position="float" fig-type="FIGURE" id="cts70136-fig-0001"><label>FIGURE 1</label><caption><p>MTX pharmacological pathways shown in a simplified version. (A) Pharmacokinetic pathways; (B) pharmacodynamic pathways. Once in the cells, the folylpolyglutamate synthetase (FPGS) converts MTX into polyglutamates (MTXPGs) that are retained into cells for a prolonged period. MTXPGs are irreversible competitive inhibitors of the target enzyme dihydrofolate reductase (DHFR) that catalyzes the conversion of dihydrofolate (DHF) into tetrahydrofolate (THF), an important cofactor of de novo purine synthesis and a major one&#x02010;carbon carrier in the body. Additionally, MTXPGs impair several other enzymes, such as 5,10&#x02010;methylenetetrahydrofolate reductase (MTHFR), involved in folate metabolism, DNA replication, and methylation of both DNA and protein and thymidylate synthetase (TYMS), involved in the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Adapted from pharmGKB (<ext-link xlink:href="https://www.pharmgkb.org/pathway/PA165816349" ext-link-type="uri">https://www.pharmgkb.org/pathway/PA165816349</ext-link>).</p></caption><graphic xlink:href="CTS-18-e70136-g001" position="anchor" id="jats-graphic-1"/></fig><p>Being a nonselective drug, MTX may affect both tumoral and healthy rapidly dividing cells, leading to severe toxicities of normal tissues, and thus to therapy interruption or discontinuation [<xref rid="cts70136-bib-0010" ref-type="bibr">10</xref>, <xref rid="cts70136-bib-0011" ref-type="bibr">11</xref>, <xref rid="cts70136-bib-0012" ref-type="bibr">12</xref>]. Incidence and severity of drug&#x02010;related adverse reactions depend on exposure intensity [<xref rid="cts70136-bib-0013" ref-type="bibr">13</xref>]. Toxicity of low doses MTX primarily manifests as moderate myelosuppression and hepatotoxicity in ALL patients. In contrast, patients receiving HD&#x02010;MTX are at risk of severe hematologic, gastrointestinal, and hepatic side effects; indeed, supplemental folinic acid intravenous infusions are given post HD&#x02010;MTX as a &#x0201c;rescue&#x0201d; therapy for healthy cells. Moreover, supportive measurements such as urine alkalinization and hydration are recommended since the massive urine excretion of MTX may exceed drug solubility and lead to drug crystallization and nephrotoxicity. Nonetheless, the troubling occurrence of HD&#x02010;MTX&#x02010;induced toxicities often results from variability in MTX pharmacokinetics (PK), and remains a concern.</p><p>In the last decade, genome&#x02010;wide association studies (GWAS) and/or candidate gene analysis have investigated the contribution of single nucleotide polymorphism (SNP) on HD&#x02010;MTX PK and clinical outcomes [<xref rid="cts70136-bib-0014" ref-type="bibr">14</xref>, <xref rid="cts70136-bib-0015" ref-type="bibr">15</xref>, <xref rid="cts70136-bib-0016" ref-type="bibr">16</xref>]. The role of some genetic variants in <italic toggle="yes">SLCO1B1</italic>, <italic toggle="yes">ABCB1</italic>, <italic toggle="yes">ABCC2</italic>, <italic toggle="yes">ABCC3</italic>, and <italic toggle="yes">ABCC4</italic> genes emerged (Table&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S1</xref>); however, their contribution have never been evaluated in ALL protocols of the European AIEOP&#x02010;BFM consortium. Therefore, we investigate the potential role of candidate polymorphisms in <italic toggle="yes">SLCO1B1</italic> (rs4149056 and rs2306283), <italic toggle="yes">ABCB1</italic> (rs1045642), <italic toggle="yes">ABCC2</italic> (rs717620), <italic toggle="yes">ABCC3</italic> (rs9895420), and <italic toggle="yes">ABCC4</italic> (rs7317112) on HD&#x02010;MTX PK and on patients' outcome (meant both as relapse and drug&#x02010;related toxicities during the consolidation phase) in an Italian cohort of ALL pediatric patients treated according to the AIEOP&#x02010;BFM ALL 2009 protocol.</p></sec><sec sec-type="materials-and-methods" id="cts70136-sec-0004"><label>2</label><title>Materials and Methods</title><sec id="cts70136-sec-0005"><label>2.1</label><title>Study Population</title><p>HD&#x02010;MTX pharmacological parameters were measured in a cohort of newly diagnosed Philadelphia&#x02013;negative ALL pediatric patients (age: 1&#x02013;18&#x02009;years). The cohort comprised 204 ALL pediatric patients enrolled between 2012 and 2017 at the Hemato&#x02010;oncological Units of the Hospitals IRCCS &#x0201c;Burlo Garofolo&#x0201d; in Trieste (<italic toggle="yes">n</italic>&#x02009;=&#x02009;33, 16.2%), &#x0201c;Regina Margherita&#x0201d; in Turin (<italic toggle="yes">n</italic>&#x02009;=&#x02009;30, 14.7%), &#x0201c;IRCCS San Gerardo dei Tintori&#x0201d; in Monza (<italic toggle="yes">n</italic>&#x02009;=&#x02009;83, 40.7%), and &#x0201c;Bambino Ges&#x000f9;&#x0201d; in Rome (<italic toggle="yes">n</italic>&#x02009;=&#x02009;58, 28.4%) in Italy. These patients were treated according to the AIEOP&#x02010;BFM ALL 2009 protocol (<ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>: NCT01117441) and fell in the standard&#x02010; and intermediate&#x02010;risk class receiving protocol M as consolidation phase. High&#x02010;risk patients were excluded from the study because not eligible to consolidation protocol M; Down Syndrome children were excluded because of their differently planned HD&#x02010;MTX therapeutic scheme (a dose of 0.5&#x02009;g/m<sup>2</sup> in the first MTX course is recommended), due to their poor drug tolerance and higher frequency of drug&#x02010;related adverse effects [<xref rid="cts70136-bib-0017" ref-type="bibr">17</xref>].</p><p>Protocol M lasted 56&#x02009;days and consisted of daily oral administration of mercaptopurine&#x000a0;(MP, 25&#x02009;mg/m<sup>2</sup>) and four courses of HD&#x02010;MTX (5&#x02009;g/m<sup>2</sup>, regardless of age), given every other week since day +8. Dose adjustments were allowed in subsequent courses when children experienced episodes of severe MTX toxicity with the standard dose. HD&#x02010;MTX was administered as intravenous infusion over 24&#x02009;h (h), with a 10% loading dose over 0.5&#x02009;h. By protocol, MTX plasma levels were measured at 24&#x02009;h (end of infusion) and 42&#x02009;h; in case of delayed drug excretion (i.e., MTX concentration greater than 0.5&#x02009;&#x003bc;M), additional monitoring was planned every 6&#x02009;h. Standard leucovorin rescue (7.5&#x02009;mg/m<sup>2</sup>) occurred at 42&#x02009;h and every 6&#x02009;h, with a minimum of three doses or until MTX plasma concentration was lower than 0.25&#x02009;&#x003bc;M; leucovorin dosage could be increased if necessary according to AIEOP&#x02010;BFM ALL 2009 protocol guidelines. Standard supportive care guidelines included hyperhydration (3000&#x02009;mL/ m<sup>2</sup>/day) and urine alkalinization (pH &#x0003e;&#x02009;7), continued until MTX plasma concentration lower than 0.25&#x02009;&#x003bc;M. Information of other concomitant medications used in consolidation was not available.</p><p>The study was approved by the Institutional Review Board (or Ethics Committee) of IRCCS Burlo Garofolo (Protocol number CE/V 135; March 5, 2012) and appropriate informed consent was obtained from patients/donors and/or their parents or guardians.</p></sec><sec id="cts70136-sec-0006"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">DNA</styled-content> Extraction and Pharmacogenetics Analysis</title><p>Total genomic DNA was isolated from patient peripheral blood collected in remission using a commercial kit (GenElute Blood Genomic DNA Kit, Sigma&#x02010;Aldrich, Milan, Italy) according to the manufacturer's instruction, and stored at &#x02212;20&#x000b0;C until use. TaqMan SNP genotyping assays were used (<italic toggle="yes">SLCO1B1</italic> rs2306283 assay ID: C__1901697_20, <italic toggle="yes">SLCO1B1</italic> rs4149056: C__30633906_10, <italic toggle="yes">ABCB1</italic> rs1045642: C__7586657_20, <italic toggle="yes">ABCC2</italic> rs717620: C__2814642_10, <italic toggle="yes">ABCC3</italic> rs9895420: C__27850763_10, <italic toggle="yes">ABCC4</italic> rs7317112: C__29165801_20; Applied Biosystems, Foster City, CA).</p></sec><sec id="cts70136-sec-0007"><label>2.3</label><title>Pharmacokinetics Analysis</title><p>MTX plasma concentration were measured by Syva methotrexate assay kit (Siemens). Measurements of MTX plasma concentration were available for 814 HD&#x02010;MTX courses in 204 patients. Four patients did not receive infusion at 5&#x02009;g/m<sup>2</sup> in their first course for clinical decision, and were excluded from the analysis to avoid confounding clinical situation. MTX clearance was estimated based on at least two MTX plasma concentrations per course up to all available measurements fitted to a two&#x02010;compartmental linear pharmacokinetic model with first&#x02010;order elimination and a Bayesian approach, via ADAPT software (University of Southern California, Los Angeles, CA). Both dosing intervals (0&#x02013;0.5&#x02009;h and 0.5&#x02013;24&#x02009;h) with individual dosing rates were included in the model. Model parameters were kindly provided by Prof. Carl Panetta and Prof. William Evans (Saint Jude Children Research Hospital, Memphis, Tennessee, USA). Initial estimates of apparent volume of distribution and rate constants between compartments were set as follows: <italic toggle="yes">V</italic>&#x02009;=&#x02009;9.03&#x02009;&#x000b1;&#x02009;4.70&#x02009;L/m<sup>2</sup>, ke&#x02009;=&#x02009;0.7&#x02009;&#x000b1;&#x02009;0.22&#x02009;h<sup>&#x02212;1</sup>, kcp&#x02009;=&#x02009;0.08&#x02009;&#x000b1;&#x02009;0.050&#x02009;h<sup>&#x02212;1</sup>, and kpc&#x02009;=&#x02009;0.11&#x02009;&#x000b1;&#x02009;0.0038&#x02009;h<sup>&#x02212;1</sup> [<xref rid="cts70136-bib-0018" ref-type="bibr">18</xref>]. Two different bicompartmental models (LR or SHR) have been used to analyze data based on the HD&#x02010;MTX dose actually infused (&#x0003c;&#x02009;4&#x02009;g/m<sup>2</sup> or &#x02265;&#x02009;4&#x02009;g/m<sup>2</sup>, respectively).</p></sec><sec id="cts70136-sec-0008"><label>2.4</label><title>Clinical Data</title><p>Clinical data were retrieved from the AIEOP central database on February 2022, whereas pediatricians collected toxicities retrospectively, blinded to results of pharmacological analysis. At February 2019, all patients were out of therapy. Relapses were defined according to routine clinical practice and occurred at any time in the follow&#x02010;up period (Table&#x000a0;<xref rid="cts70136-tbl-0001" ref-type="table">1</xref>). Hematological toxicity (HEM) and gastrointestinal toxicities (GI) were graded referring to a simplified version of the National Cancer Institute&#x02010;Common Terminology Criteria scales, regardless of their time of occurrence during consolidation. Severe HEM toxicities (grade &#x02265;&#x02009;3) consisted in bone marrow suppression, with episodes of hemoglobin &#x0003c;&#x02009;8&#x02009;g/dL or white blood cells (WBC) &#x0003c;&#x02009;2 &#x000d7;&#x02009;10<sup>9</sup>/L or granulocytes &#x0003c;&#x02009;1 &#x000d7;&#x02009;10<sup>9</sup>/L or platelets &#x0003c;&#x02009;50 &#x000d7;&#x02009;10<sup>9</sup>/L. Severe GI (grade &#x02265;&#x02009;3) consisted in painful stomatitis or diarrhea (with more than 7 stools/day, or bloody stools, or incontinence, or severe cramps), and impaired enteral feeding.</p><table-wrap position="float" id="cts70136-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Demographic and clinical data of the study population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Italian cohort</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total patients</td><td align="center" valign="top" rowspan="1" colspan="1">204</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Age (<italic toggle="yes">n</italic>&#x02009;=&#x02009;204)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (IQR), years</td><td align="center" valign="top" rowspan="1" colspan="1">4.85 (2.99&#x02013;8.30)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Gender (<italic toggle="yes">n</italic>&#x02009;=&#x02009;204)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">113 (55.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">91 (44.6)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Ethnic group (<italic toggle="yes">n</italic>&#x02009;=&#x02009;204)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">European ancestry, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">195 (95.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Others, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (4.4)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Immunotyping (<italic toggle="yes">n</italic>&#x02009;=&#x02009;202)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">LLA&#x02010;B, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">182 (90.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">LLA&#x02010;T, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (9.9)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Risk class (<italic toggle="yes">n</italic>&#x02009;=&#x02009;204)<xref rid="cts70136-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Standard, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">74 (36.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medium, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">130 (63.7)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High, <italic toggle="yes">n</italic>&#x000b0; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Toxicities during consolidation (Grades 3&#x02013;5<xref rid="cts70136-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>, <italic toggle="yes">n</italic>&#x02009;=&#x02009;88)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HEM, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (48.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GI, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (15.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Infections, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.5)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pancreatitis, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Renal toxicity, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Neurological toxicity, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cardiotoxicity, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Outcome (<italic toggle="yes">n</italic>&#x02009;=&#x02009;200)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Complete remission (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">173 (86.5)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Relapse, <italic toggle="yes">n</italic>&#x000b0; (%<xref rid="cts70136-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (13.5)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (IQR) in years to relapse</td><td align="center" valign="top" rowspan="1" colspan="1">2.6 (1.7&#x02013;3.3)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Follow&#x02010;up</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median (IQR) in years since diagnosis, <italic toggle="yes">N</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.2 (4.6&#x02013;6.4), 199</td></tr></tbody></table><table-wrap-foot id="cts70136-ntgp-0002"><fn id="cts70136-note-0003"><p>Abbreviations: GI, gastrointestinal toxicity; HEM, hematological toxicity; IQR, interquartile range; LLA&#x02010;B, LLA&#x02010;immunophenotype B; LLA&#x02010;T, LLA&#x02010;immunophenotype T; <italic toggle="yes">n</italic>&#x000b0;, numbers; Na, not available.</p></fn><fn id="cts70136-note-0004"><label>
<sup>a</sup>
</label><p>Percentage compared to available data.</p></fn><fn id="cts70136-note-0005"><label>
<sup>b</sup>
</label><p>Risk range at the end of the induction phase.</p></fn><fn id="cts70136-note-0006"><label>
<sup>c</sup>
</label><p>Severe HEM toxicities (grade&#x02009;&#x02265;&#x02009;3) consisted in bone marrow suppression, with episodes of hemoglobin &#x0003c;&#x02009;8&#x02009;g/dL or white blood cells (WBC) &#x0003c;&#x02009;2 &#x000d7;&#x02009;10<sup>9</sup>/L or granulocytes &#x0003c;&#x02009;1 &#x000d7;&#x02009;10<sup>9</sup>/L or platelets &#x0003c;&#x02009;50 &#x000d7;&#x02009;10<sup>9</sup>/L. Severe GI (grade &#x02265;&#x02009;3) consisted in painful stomatitis or diarrhea (with more than 7 stools/day, or bloody stools, or incontinence or severe cramps), and impaired oral feeding.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cts70136-sec-0009"><label>2.5</label><title>Statistical Analysis</title><p>Statistical analyses were performed using the software R version 3.5.2. MTX plasma levels and clearance were calculated for each cycle and considered as average measurement per patient, when not otherwise written. Intra&#x02010;patient variability of PK parameters was assessed as coefficient of variation (CV). PK parameters were analyzed both as continuous variables and as quartiles (i.e., Q<sub>1</sub>&#x02013;Q<sub>4</sub>; Q<sub>1</sub> representing the lower quartile and Q<sub>4</sub> the upper one); MTX systemic exposure was considered &#x0201c;high&#x0201d; either when MTX plasma levels correspond to upper values (continuous data)/Q<sub>4</sub> (categorical data) or when the MTX clearances correspond to lower values (continuous data)/Q<sub>1</sub> (categorical data), this latter case corresponding to a delayed drug elimination. Normality of continuous data was examined using the Shapiro&#x02013;Wilk test. The association between PK parameters (dependent variable) and pharmacogenomic and demographic variables (independent variables) was examined using linear models of the Gaussian family and linear mixed effect models; pharmacogenetic contribution were evaluated according to additive, dominant and recessive models of the minor alleles on the phenotype of interest. Age group were defined according to a cutoff value, arbitrarily set at 10&#x02009;years, to account for different hormonal/developmental stage of patients (&#x0201c;children&#x0201d; vs. &#x0201c;adolescents&#x0201d;) and for survival disadvantage and increased occurrence of drug&#x02010;related adverse effects observed in older pediatric ALL patients compared to younger ones [<xref rid="cts70136-bib-0019" ref-type="bibr">19</xref>, <xref rid="cts70136-bib-0020" ref-type="bibr">20</xref>].</p><p>The follow&#x02010;up time was calculated from diagnosis to the date of last available contact or the occurrence of an event (relapse, death, or second neoplasm), whichever came first. The Cox proportion hazard model was adopted for evaluating the impact of genotypes and MTX systemic exposure/clearance/intra&#x02010;patient variability on relapse.</p><p>Treatment&#x02010;related HEM and GI toxicities in consolidation were considered as dependent variables. Other drug&#x02010;related adverse effects incidence lower than 5% were not considered in the analysis. Adverse effects were dichotomized as severe (grades 3&#x02013;5) versus non&#x02010;severe (grades 1&#x02013;2 or absent), without discriminating among specific adverse episodes. Kruskal&#x02013;Wallis test was used to investigate the influence of pharmacokinetic parameters on HEM and GI toxicities, considered separately. Associations between categorical variables were explored via Fisher's exact test (i.e., SNP genotypes on HEM and GI).</p></sec></sec><sec sec-type="results" id="cts70136-sec-0010"><label>3</label><title>Results</title><sec id="cts70136-sec-0011"><label>3.1</label><title>Patient Characteristics and Pharmacological Analysis: <styled-content style="fixed-case" toggle="no">SNP</styled-content> Genotyping and <styled-content style="fixed-case" toggle="no">MTX</styled-content> Pharmacokinetics</title><p>Patient characteristics are shown in Table&#x000a0;<xref rid="cts70136-tbl-0001" ref-type="table">1</xref>. Genotype distributions of candidate SNPs are shown in Table&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><p>Pharmacokinetic parameters of 798 HD&#x02010;MTX courses in 200 patients are reported in Table&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3</xref>. Twelve patients could not tolerate HD&#x02010;MTX infusions at the planned dose of 5&#x02009;g/m<sup>2</sup>: Six patients reduced HD&#x02010;MTX from 2nd infusion, other four patients from 3rd on, and two patients received lower dosages at 4th infusion (28 courses in total). By protocol, the expected end&#x02010;of&#x02010;infusion concentration at 24&#x02009;h should be lower than 150&#x02009;&#x003bc;M; five patients exceeded this concentration in five courses (0.6% of total infusions). Median plasma MTX level at 24&#x02009;h was 41.09&#x02009;&#x003bc;M (interquartile range [IQR]: 31.68&#x02013;53.70&#x02009;&#x003bc;M), with similar intercourse values (Table&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3</xref>, Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S1A</xref>); intra&#x02010;patient variability in end&#x02010;of&#x02010;infusion concentrations was 31.3% (22.71%&#x02013;45.72%). Post&#x02010;infusion MTX levels at 42 and 48&#x02009;h were 0.54 (0.39&#x02013;0.88) &#x003bc;M (798 samples in 200 patients) and 0.39 (0.28&#x02013;0.63) &#x003bc;M (530 samples in 169 patients), respectively. Intercourse analysis showed decreased drug concentrations at both time points in late HD&#x02010;MTX cycles (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;10<sup>&#x02212;4</sup> and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002, respectively, Kruskal&#x02013;Wallis test, Table&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3</xref> and Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S1B,C</xref>). About 15% of MTX plasma levels were above the expected 1&#x02009;&#x003bc;M threshold at 42&#x02009;h and about 29% above the expected 0.5&#x02009;&#x003bc;M at 48&#x02009;h; patients with exceeding values received according to the therapeutic protocol higher leucovorin rescue. Calculated MTX clearance in 200 patients was 159.80 (123.76&#x02013;192.04) mL/min/m<sup>2</sup>, with similar median values among HD&#x02010;MTX cycles (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S1D</xref>). Intra&#x02010;patient variability in MTX clearance was 24.20% (16.03%&#x02013;32.25%).</p></sec><sec id="cts70136-sec-0012"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">MTX</styled-content> Plasma Concentrations Are Higher in Older Patients and <styled-content style="fixed-case" toggle="no">ABCC4</styled-content> rs7317112 Wild&#x02010;Type Carriers</title><p>MTX overall systemic exposure was affected by age, with older patients showing higher drug plasma levels at the end of infusion and delayed elimination compared to younger children (Table&#x000a0;<xref rid="cts70136-tbl-0002" ref-type="table">2</xref>, Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S2</xref>). Gender did not affect MTX pharmacokinetic parameters. Among candidate SNPs, <italic toggle="yes">ABCC4</italic> rs7317112 variant significantly reduced HD&#x02010;MTX exposure in univariate analysis (Table&#x000a0;<xref rid="cts70136-tbl-0002" ref-type="table">2</xref>, Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3</xref>). MTX plasma concentrations were lower in homozygous variant GG patients compared to those carrying at least one A wild&#x02010;type allele, both at 24&#x02009;h (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3A</xref>) and at 42&#x02009;h (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3B</xref>). <italic toggle="yes">ABCC4</italic> rs7317112 variant resulted in an accelerated elimination of the drug (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S3D</xref>). Multivariate analysis confirmed the independent contribution of age and <italic toggle="yes">ABCC4</italic> SNP rs7317112 on pharmacokinetic parameters (Table&#x000a0;<xref rid="cts70136-tbl-0002" ref-type="table">2</xref>). When patients were grouped according to age (cutoff arbitrarily set at 10&#x02009;years) and <italic toggle="yes">ABCC4</italic> SNP rs7317112 (GG/non&#x02010;GG genotypes), MTX plasma levels at 24, 42, and 48&#x02009;h were lower for young rs7317112 GG patients (group A) compared to rs7317112 non&#x02010;GG teens (group D), with a clearly higher clearance of the drug (Figure&#x000a0;<xref rid="cts70136-fig-0002" ref-type="fig">2</xref>).</p><table-wrap position="float" id="cts70136-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Multivariate analysis on average end&#x02010;of&#x02010;infusion methotrexate plasma levels and clearance in the study population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">MTX plasma levels (24&#x02009;h)</th><th align="center" colspan="5" valign="bottom" rowspan="1">Univariate</th><th align="center" colspan="5" valign="bottom" rowspan="1">Multivariate</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
<xref rid="cts70136-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Coefficient</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Coefficient</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (each year)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">4.58 &#x000d7;&#x02009;10<sup>&#x02212;6</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">3.11 &#x000d7;&#x02009;10<sup>&#x02212;7</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.66 &#x000d7;&#x02009;10<sup>&#x02212;12</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (female vs. male)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SLCO1B1</italic> rs2306283 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">0.107</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SLCO1B1</italic> rs4149056 (non CC vs. CC)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCB1</italic> rs1045642 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC2</italic> rs717620 (TT vs. non TT)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC3</italic> rs9895420 (non AA vs. AA)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC4</italic> rs7317112 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1">4.61 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;7</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;6</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Clearance</th><th align="center" colspan="5" valign="bottom" rowspan="1">Univariate</th><th align="center" colspan="5" valign="bottom" rowspan="1">Multivariate</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Coefficient</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Coefficient</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (each year)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.19</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.02</td><td align="center" valign="top" rowspan="1" colspan="1">2.98 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;8</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.46</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.02</td><td align="center" valign="top" rowspan="1" colspan="1">1.57 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;8</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.64 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;12</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (female vs. male)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.48</td><td align="center" valign="top" rowspan="1" colspan="1">4.62</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;15.54</td><td align="center" valign="top" rowspan="1" colspan="1">2.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SLCO1B1</italic> rs2306283 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;16.21</td><td align="center" valign="top" rowspan="1" colspan="1">6.39</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;28.73</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.68</td><td align="center" valign="top" rowspan="1" colspan="1">1.14 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;2</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.12</td><td align="center" valign="top" rowspan="1" colspan="1">6.51</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;28.73</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.68</td><td align="center" valign="top" rowspan="1" colspan="1">4.43 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;2</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SLCO1B1</italic> rs4149056 (non CC vs. CC)</td><td align="center" valign="top" rowspan="1" colspan="1">31.78</td><td align="center" valign="top" rowspan="1" colspan="1">13.53</td><td align="center" valign="top" rowspan="1" colspan="1">5.26</td><td align="center" valign="top" rowspan="1" colspan="1">58.30</td><td align="center" valign="top" rowspan="1" colspan="1">1.90 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;2</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">17.16</td><td align="center" valign="top" rowspan="1" colspan="1">14.87</td><td align="center" valign="top" rowspan="1" colspan="1">5.26</td><td align="center" valign="top" rowspan="1" colspan="1">58.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCB1</italic> rs1045642 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">2.78</td><td align="center" valign="top" rowspan="1" colspan="1">5.59</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.17</td><td align="center" valign="top" rowspan="1" colspan="1">13.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC2</italic> rs717620 (TT vs. non TT)</td><td align="center" valign="top" rowspan="1" colspan="1">5.47</td><td align="center" valign="top" rowspan="1" colspan="1">11.828</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;17.71</td><td align="center" valign="top" rowspan="1" colspan="1">28.66</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC3</italic> rs9895420 (non AA vs. AA)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;20.58</td><td align="center" valign="top" rowspan="1" colspan="1">19.11</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;58.04</td><td align="center" valign="top" rowspan="1" colspan="1">16.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ABCC4</italic> rs7317112 (non GG vs. GG)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;38.74</td><td align="center" valign="top" rowspan="1" colspan="1">8.63</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;55.67</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;21.82</td><td align="center" valign="top" rowspan="1" colspan="1">8.39 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;6</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;36.25</td><td align="center" valign="top" rowspan="1" colspan="1">8.46</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;52.83</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;21.82</td><td align="center" valign="top" rowspan="1" colspan="1">2.06 &#x000d7;&#x02009;10<sup>
<bold>&#x02212;5</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cts70136-ntgp-0003"><fn id="cts70136-note-0007"><p>
<italic toggle="yes">Note:</italic> Genetic contribution is presented according to a recessive model of minor allele (mutated vs. non mutated genotypes).</p></fn><fn id="cts70136-note-0008"><p>Abbreviations: CI, 95% confidence interval; SE, Standard error.</p></fn><fn id="cts70136-note-0009"><label>
<sup>a</sup>
</label><p>Likelihood ratio test. The coefficient of the interaction term between age and <italic toggle="yes">ABCC4</italic> rs7317112 was 6.3 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;6.39 &#x000d7;&#x02009;10<sup>&#x02212;3</sup>) for clearance.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cts70136-fig-0002"><label>FIGURE 2</label><caption><p>Methotrexate systemic exposure according to age and <italic toggle="yes">ABCC4</italic> SNP rs7317112. Patients were grouped according to age (dichotomized as &#x0201c;children&#x0201d; vs. &#x0201c;teens&#x0201d; by an arbitrary cutoff set at 10&#x02009;years) and <italic toggle="yes">ABCC4</italic> SNP rs7317112 genotypes (dichotomized as mutated GG vs. non mutated), resulting in group A (GG children), group B (non&#x02010;GG children), group C (GG teens), and group D (non&#x02010;GG teens). Blue lines indicate the expected thresholds level of MTX at different time points; blue numbers in parentheses above the box plots indicated the number of patients (and percentage) above thresholds who received intensified leucovorin rescue. <italic toggle="yes">p</italic>&#x02010;value calculated according to Kruskal&#x02013;Wallis test; + significance according to the Dunn test for multiple comparison.</p></caption><graphic xlink:href="CTS-18-e70136-g002" position="anchor" id="jats-graphic-3"/></fig><p>Both SNPs in <italic toggle="yes">SLCO1B1</italic> were associated with pharmacokinetic parameters in univariate analysis, with opposite contribution of variant homozygous genotype on MTX plasma levels and clearance; however, only rs2306283 retained a borderline association with clearance after multivariate analysis.</p></sec><sec id="cts70136-sec-0013"><label>3.3</label><title>Higher <styled-content style="fixed-case" toggle="no">MTX</styled-content> Systemic Exposure and <styled-content style="fixed-case" toggle="no">ABCC2</styled-content> rs717620 Variant Allele Increased Risk of Severe Hematological Toxicities in Consolidation</title><p>The incidence of HEM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;43 (48.9%)) and GI (<italic toggle="yes">n</italic>&#x02009;=&#x02009;14 (15.9%)) toxicity was not affected by age or gender (Table&#x000a0;<xref rid="cts70136-tbl-0003" ref-type="table">3</xref>). The T&#x02010;variant allele of the <italic toggle="yes">ABCC2</italic> SNP rs717620 was a risk allele for both HEM and GI severe toxicities (wild&#x02010;type CC vs. CT&#x02009;+&#x02009;TT carriers: HEM: 37.7% vs. 74.1%, Fisher test: <italic toggle="yes">p</italic>&#x02009;=&#x02009;4.1 &#x000d7;&#x02009;10<sup>&#x02212;3</sup>; GI: 7.5% vs. 29.6%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;1.7 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>). A higher incidence of HEM was observed for carriers of <italic toggle="yes">SLCO1B1</italic> rs2306283 GG variant genotype compared to those carrying at least one wild&#x02010;type A allele (55.9% vs. 18.2%, respectively, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.03).</p><table-wrap position="float" id="cts70136-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Pharmacogenetics contribution on patient's toxicities.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" rowspan="2" valign="bottom" colspan="1">Tot</th><th align="center" colspan="4" valign="bottom" rowspan="1">HEM</th><th align="center" colspan="4" valign="bottom" rowspan="1">GI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Yes (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR</th><th align="center" valign="bottom" rowspan="1" colspan="1">CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Yes (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR</th><th align="center" valign="bottom" rowspan="1" colspan="1">CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="10" valign="top" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;10&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">32 (48.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.34&#x02013;3.27</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">10 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.28&#x02013;5.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;10&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">10 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Gender</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">24 (42.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#x02013;5.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">10 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.15&#x02013;2.73</td><td align="center" valign="top" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">19 (61.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4 (12.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">SLCO1B1</italic> rs2306283</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;GG</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">5.58</td><td align="center" valign="top" rowspan="1" colspan="1">1.04&#x02013;56.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">1 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.20&#x02013;82.2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">38 (55.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10 (14.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">SLCO1B1</italic> rs4149056</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;CC</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2 (66.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.01&#x02013;9.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">1 (33.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.02&#x02013;21.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CC</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">37 (50.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11 (14.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">ABCB1</italic> rs1045642</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;GG</td><td align="center" valign="top" rowspan="1" colspan="1">59</td><td align="center" valign="top" rowspan="1" colspan="1">27 (45.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#x02013;1.60</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td><td align="center" valign="top" rowspan="1" colspan="1">9 (15.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.23&#x02013;6.88</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">13 (61.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">ABCC2</italic> rs717620</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;CC</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">20 (74.1)</td><td align="center" valign="top" rowspan="1" colspan="1">4.62</td><td align="center" valign="top" rowspan="1" colspan="1">1.54&#x02013;15.39</td><td align="center" valign="top" rowspan="1" colspan="1">4.11 &#x000d7;&#x02009;10<sup>&#x02212;3</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">8 (29.6)</td><td align="center" valign="top" rowspan="1" colspan="1">5.04</td><td align="center" valign="top" rowspan="1" colspan="1">1.18&#x02013;25.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.73 &#x000d7;&#x02009;10<sup>&#x02212;2</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CC</td><td align="center" valign="top" rowspan="1" colspan="1">53</td><td align="center" valign="top" rowspan="1" colspan="1">20 (37.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">ABCC3</italic> rs9895420</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;AA</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">36 (50.7)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">10 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AA</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">
<italic toggle="yes">ABCC4</italic> rs7317112</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;GG</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">36 (50.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.01&#x02013;4.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">11 (15.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.04&#x02013;31.46</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">3 (75.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">CL mean</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q1</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">1.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.40&#x02013;2.69</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1">0.10&#x02013;1.91</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q2&#x02013;Q4</td><td align="center" valign="top" rowspan="1" colspan="1">49</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cts70136-ntgp-0004"><fn id="cts70136-note-0010"><p>Abbreviations: GI, Gastrointestinal toxicities; HEM, Hematological toxicities.</p></fn></table-wrap-foot></table-wrap><p>Increased systemic exposure to MTX, indicated by mean clearance values per patient in the lower quartile (Q1) was not associated with HEM or GI occurrence during consolidation (Table&#x000a0;<xref rid="cts70136-tbl-0003" ref-type="table">3</xref>). However, when each infusion was analyzed separately, patients who developed HEM showed higher end&#x02010;of&#x02010;infusion plasma levels (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S4A</xref>, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.013) and lower clearance (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S4B</xref>, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.010) after the first course compared to those who did not. A tendency toward higher plasma concentration (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S4C</xref>, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.052) and a significant delay in drug elimination (Figure&#x000a0;<xref rid="cts70136-supitem-0001" ref-type="supplementary-material">S4D</xref>, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02) was observed also after the second course. No association was found with pharmacokinetic parameters of subsequent cycles.</p><p>After multiple corrections, only the association between <italic toggle="yes">ABCC2</italic> SNP rs717620 and HEM remained significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.005).</p></sec><sec id="cts70136-sec-0014"><label>3.4</label><title>
<styled-content style="fixed-case" toggle="no">SLCO1B1 SNP</styled-content> rs4149056 Decreased the Risk of Relapse</title><p>The impact of demographic variants on patients' outcomes was analyzed, showing a significant association of age, when patients were categorized as younger or older than 10&#x02009;years. In particular, older children showed a 2.39 hazard risk (HR) or relapse (confidence interval [CI]:1.07&#x02013;5.32, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.03, Table&#x000a0;<xref rid="cts70136-tbl-0004" ref-type="table">4</xref>). The impact of genetic variants on patients' outcomes was first analyzed by using an additive genetic model, suggesting a contribution of <italic toggle="yes">SLCO1B1</italic> SNP rs4149056 on relapse risk (Table&#x000a0;<xref rid="cts70136-tbl-0004" ref-type="table">4</xref>). When a dominant model for the minor allele was applied, patients with at least one rs4149056 variant C&#x02010;allele showed a reduced risk of relapse compared to wild&#x02010;type TT carriers (hazard risk [HR]: 0.29, 95% CI: 0.09&#x02013;0.98, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.047). Other genetic variables were not significantly associated with relapse risk. To evaluate the possible impact of MTX exposure on patients' outcomes, mean MTX plasma levels at the end of infusion and clearance were considered as quartile (Q1&#x02013;Q4). MTX systemic exposure was considered &#x0201c;high&#x0201d; when end&#x02010;of&#x02010;infusion MTX fell in the upper quartile (mean MTX (24&#x02009;h)&#x02010;Q4) and clearance in the lower one (mean CL&#x02010;Q1). A delayed clearance (mean CL&#x02010;Q1) doubled the risk of relapse (HR: 2.3, CI: 1.06&#x02013;5.12, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.035, Table&#x000a0;<xref rid="cts70136-tbl-0004" ref-type="table">4</xref>). The delayed clearance did not affect the number and/or the doses of subsequent courses of HD&#x02010;MTX administered (data not shown); however, 26 out of 39 patients with delayed clearance (66.6% mean CL, Q1) and 53 out of 135 patients in the other group (39.2% mean CL, Q2&#x02013;Q4) require to continue leucovorin rescue at 48&#x02009;h in at least one course because of MTX plasma levels exceeding 0.5&#x02009;&#x003bc;M: the difference was significant (OR: 4.25, 95%CI: 1.98&#x02013;9.59, Fisher test, <italic toggle="yes">p</italic>&#x02009;=&#x02009;5.0 &#x000d7;&#x02009;10<sup>&#x02212;5</sup>). Low systemic exposure (meant as mean MTX (24&#x02009;h)&#x02010;Q1 and mean CL&#x02010;Q4) was not associated with relapse risk.</p><table-wrap position="float" id="cts70136-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Pharmacological parameters and patient's relapse risk.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">N</italic> patients (relapse)</th><th align="center" colspan="3" valign="bottom" rowspan="1">Univariate</th><th align="center" colspan="3" valign="bottom" rowspan="1">Multivariate</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
<xref rid="cts70136-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
<xref rid="cts70136-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="8" valign="top" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;10&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">156 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;10&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">36 (9)</td><td align="center" valign="top" rowspan="1" colspan="1">2.39 (1.07&#x02013;5.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.14 (0.90&#x02013;5.05)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">Gender</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">106 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">86 (10)</td><td align="center" valign="top" rowspan="1" colspan="1">1.47 (0.67&#x02013;3.22)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">SLCO1B1</italic> rs2306283</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AA</td><td align="center" valign="top" rowspan="1" colspan="1">59 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AG</td><td align="center" valign="top" rowspan="1" colspan="1">92 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">2.28 (0.83&#x02013;6.21)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">29 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.16 (0.28&#x02013;4.88)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">SLCO1B1</italic> rs4149056</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TT</td><td align="center" valign="top" rowspan="1" colspan="1">128 (22)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TC</td><td align="center" valign="top" rowspan="1" colspan="1">49 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.22 (0.05&#x02013;0.93)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CC</td><td align="center" valign="top" rowspan="1" colspan="1">6 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.12&#x02013;6.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.90</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.27 (0.08&#x02013;0.90)<xref rid="cts70136-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.037</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">ABCB1</italic> rs1045642</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">40 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GA</td><td align="center" valign="top" rowspan="1" colspan="1">94 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.31&#x02013;2.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AA</td><td align="center" valign="top" rowspan="1" colspan="1">49 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.35&#x02013;2.93)</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">ABCC2</italic> rs717620</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CC</td><td align="center" valign="top" rowspan="1" colspan="1">123 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">53 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.73 (0.29&#x02013;1.85)</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TT</td><td align="center" valign="top" rowspan="1" colspan="1">6 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.13&#x02013;7.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.96</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">ABCC3</italic> rs9895420</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TT</td><td align="center" valign="top" rowspan="1" colspan="1">122 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TA</td><td align="center" valign="top" rowspan="1" colspan="1">48 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.24&#x02013;1.71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AA</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">2.80 (0.37&#x02013;21.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">
<italic toggle="yes">ABCC4</italic> rs7317112</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AA</td><td align="center" valign="top" rowspan="1" colspan="1">94 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AG</td><td align="center" valign="top" rowspan="1" colspan="1">66 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.34&#x02013;2.01)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GG</td><td align="center" valign="top" rowspan="1" colspan="1">15 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.42 (0.40&#x02013;5.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">MTX_24h_mean (quartile)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q1&#x02013;Q3</td><td align="center" valign="top" rowspan="1" colspan="1">142 (15)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q4</td><td align="center" valign="top" rowspan="1" colspan="1">49 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">1.96 (0.88&#x02013;4.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="8" valign="top" rowspan="1">CL_mean (quartile)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q2&#x02013;Q4</td><td align="center" valign="top" rowspan="1" colspan="1">142 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q1</td><td align="center" valign="top" rowspan="1" colspan="1">49 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">2.33 (1.06&#x02013;5.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.18 (0.93&#x02013;5.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cts70136-ntgp-0005"><fn id="cts70136-note-0011"><label>
<sup>a</sup>
</label><p>Likelihood ratio test.</p></fn><fn id="cts70136-note-0012"><label>
<sup>b</sup>
</label><p>As dominant model of variant allele.</p></fn></table-wrap-foot></table-wrap><p>The association between <italic toggle="yes">SLCO1B1</italic> SNP rs4149056 and relapse risk remained fully significant after multivariate analysis (protective non&#x02010;TT genotype: HR: 0.27, CI: 0.08&#x02013;0.90, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.037), whereas older age and lower clearance retained borderline significance as adverse factors (HR: 2.14 (0.90&#x02013;5.05), <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.08 and 2.18 (0.93&#x02013;5.07), <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.07, respectively, Table&#x000a0;<xref rid="cts70136-tbl-0004" ref-type="table">4</xref>, Figure&#x000a0;<xref rid="cts70136-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="cts70136-fig-0003"><label>FIGURE 3</label><caption><p>Impact of pharmacological parameters on relapse risk. (A) <italic toggle="yes">SLCO1B1</italic> rs4149056; (B) MTX clearance expressed in quartile. Q1: 1st quartile (delayed clearance); Q2: 2nd quartile; Q3: 3rd quartile; Q4: 4th quartile; (C) age (cutoff 10&#x02009;years). <italic toggle="yes">p</italic>&#x02010;value according to multivariate analysis.</p></caption><graphic xlink:href="CTS-18-e70136-g003" position="anchor" id="jats-graphic-5"/></fig></sec></sec><sec sec-type="discussion" id="cts70136-sec-0015"><label>4</label><title>Discussion</title><p>In ALL therapy, the importance of consolidating the early remission of the disease by removing undetectable residual tumoral cells is well recognized; optimization of drug intensities in this therapeutic phase is therefore mandatory to achieve a sustained event&#x02010;free survival. The use of oral MP combined to infusions of HD&#x02010;MTX is common in the consolidation phase, although substantial differences in MP/HD&#x02010;MTX dosages and timing of administrations are present across ALL protocols of different cooperative groups. Pharmacogenetic and pharmacokinetic evidences generated to improve drug therapy are thus protocol&#x02010;based, and are difficult to translate among ALL trials without an appropriate validation [<xref rid="cts70136-bib-0021" ref-type="bibr">21</xref>].</p><p>Genetic variability in HD&#x02010;MTX pharmacokinetics and toxicities has been extensively investigated, but without conclusive results [<xref rid="cts70136-bib-0022" ref-type="bibr">22</xref>, <xref rid="cts70136-bib-0023" ref-type="bibr">23</xref>]. <italic toggle="yes">MTHFR</italic> SNPs rs1801133 and rs1801131, involved in MTX pharmacodynamics, are the best characterized variants [<xref rid="cts70136-bib-0023" ref-type="bibr">23</xref>, <xref rid="cts70136-bib-0024" ref-type="bibr">24</xref>]; however, these SNPs reach only a level of evidence 3 for drug&#x02013;gene association in Pharmacogenomics Knowledge Base (PharmGKB) database, and are excluded from the two highest rankings of evidence selected by Pharmacogenomic consortia (the Dutch Pharmacogenetics Working Group [DPWG] and the Clinical Pharmacogenetics Implementation Consortium [CPIC]) to develop pharmacogenetic&#x02010;based guideline [<xref rid="cts70136-bib-0025" ref-type="bibr">25</xref>]. This is likely due to several reasons including, among others, the low&#x02010;penetrance of variants considered, the variety and complexity of metabolic pathways with which MTX interferes, and the complex clinical traits taken into account. In contrast, pharmacogenetic&#x02010;based guidelines for MP are currently available since the role of <italic toggle="yes">TPMT</italic> and <italic toggle="yes">NUDT15</italic> gene variants on MP intolerances is well established [<xref rid="cts70136-bib-0025" ref-type="bibr">25</xref>], and additional contributions of variants in <italic toggle="yes">ITPA</italic> and <italic toggle="yes">PACSIN2</italic> genes are under investigation [<xref rid="cts70136-bib-0026" ref-type="bibr">26</xref>, <xref rid="cts70136-bib-0027" ref-type="bibr">27</xref>]. Pharmacokinetic variability in HD&#x02010;MTX might also affect both therapy efficacy and toxicity. Post&#x02010;infusions high interindividual variability in MTX levels have been reported in several studies, and confirmed in our study cohort. Because an adequate clearance is fundamental to maintain MTX plasma level in the therapeutic window, preventing drug adverse reactions or worst outcome, this study evaluated the impact of different pharmacogenetic variants in influx&#x02013;efflux drug transporters on HD&#x02010;MTX PK and clinical outcome in ALL pediatric patients for the first time in the specific context of the AIEOP&#x02010;BFM ALL 2009 protocol.</p><p>AIEOP&#x02010;BFM ALL 2009 protocol was in force in Italy between October 01, 2010 and February 28, 2017 enrolling 2098 patients (1576 [75%] not at high risk). With 204 patients, our study population represent a small subset cohort of AIEOP&#x02010;BFM ALL 2009 treated patients; however, features such as age, gender, immunophenotype, and outcome are in accordance with those previously reported [<xref rid="cts70136-bib-0028" ref-type="bibr">28</xref>, <xref rid="cts70136-bib-0029" ref-type="bibr">29</xref>], suggesting that our results might be representative for the whole cohort.</p><p>Interestingly, a contribution of age on drug systemic exposure was observed, as indicated by a delayed elimination of MTX and the need of higher doses of leucovorin in teenagers. Previous studies have already shown that systemic exposure to MTX is higher in adolescents than in children [<xref rid="cts70136-bib-0015" ref-type="bibr">15</xref>]. In the study of Zobeck et&#x000a0;al., older age conferred an increase in the odds of using carboxypeptidase G2 (CPDG2; glucarpidase), a bacterial&#x02010;derived enzyme that can rapidly reduce serum levels of MTX by hydrolysis to inactive metabolite [<xref rid="cts70136-bib-0030" ref-type="bibr">30</xref>]. These results suggest a possible role of age&#x02010;related epigenetic factors in MTX disposition. Because DNA methylation changes in growing children, it may contribute to ontogeny of enzymes involved in drug biotransformation and of transporters involved in drug elimination [<xref rid="cts70136-bib-0031" ref-type="bibr">31</xref>, <xref rid="cts70136-bib-0032" ref-type="bibr">32</xref>]. Different methylation levels in the MTX hydrolases GGH were associated with an altered expression of this gene and to a reduced enzyme activity, which affected the treatment response and was associated with MTX adverse reactions [<xref rid="cts70136-bib-0033" ref-type="bibr">33</xref>, <xref rid="cts70136-bib-0034" ref-type="bibr">34</xref>]. Doses required in children are usually higher due to an increased metabolism or drug transport [<xref rid="cts70136-bib-0035" ref-type="bibr">35</xref>]. Besides age, the significant influence of the intronic <italic toggle="yes">ABCC4</italic> SNP rs7317112 on HD&#x02010;MTX PK was found, indicating that the presence of variant G allele in the renal efflux transporter gene prompted drug elimination. <italic toggle="yes">ABCC4</italic> SNP rs7317112 is located in an enhancer region and in a CpG site, which could carry changes in the methylation pattern, and thus in the MRP4 expression. The reduced drug clearance could alter the incidence of HD&#x02010;MTX side effects; however, in our study population, <italic toggle="yes">ABCC4</italic> SNP rs7317112 genotypes did not influence the occurrence of HEM or GI. A previous study on MTX&#x02010;induced mucositis showed a protective role of the G allele [<xref rid="cts70136-bib-0036" ref-type="bibr">36</xref>]. In the study of Zobeck et&#x000a0;al., each additional G allele of rs7317112 in <italic toggle="yes">ABCC4</italic> was strongly associated with risk for requiring CPDG2, and thus likely with a reduced tubular excretion of drugs [<xref rid="cts70136-bib-0030" ref-type="bibr">30</xref>]. Grouping patients according to age (cutoff: 10&#x02009;years) and <italic toggle="yes">ABCC4</italic> SNP rs7317112 could not help identifying <italic toggle="yes">a priori</italic> intolerant patients (those who will reduce the 5&#x02009;g/m<sup>2</sup> planned doses after the first HD&#x02010;MTX cycle, data not shown). However, it could predict patients who will not exceed the expected MTX plasma levels of 150&#x02009;&#x003bc;M at 24&#x02009;h, 1&#x02009;&#x003bc;M at 42&#x02009;h, and 0.5&#x02009;&#x003bc;M at 48&#x02009;h (i.e., rs7317112 GG children younger than 10&#x02009;years) and those who will likely require an intensified leucovorin rescue (i.e., rs7317112 non&#x02010;GG teens). In perspective, an optimized HD&#x02010;MTX infusion scheme and supportive management tailored for this latter group could be proposed, although this group does not suffer of higher toxicities; however, an increased relapse rate was observed for teens and for patients with lower MTX clearance.</p><p>The results emerged in this study indicate <italic toggle="yes">ABCC2</italic> rs717620 (&#x02212;24C&#x0003e;T) as a contributing factor in the HD&#x02010;MTX adverse reaction risk, in line with previous evidences [<xref rid="cts70136-bib-0037" ref-type="bibr">37</xref>, <xref rid="cts70136-bib-0038" ref-type="bibr">38</xref>, <xref rid="cts70136-bib-0039" ref-type="bibr">39</xref>, <xref rid="cts70136-bib-0040" ref-type="bibr">40</xref>]. <italic toggle="yes">ABCC2</italic> encodes for multidrug resistance&#x02010;associated protein 2 (MRP2) that is expressed at the apical canalicular membrane of liver cells, kidney proximal tubule epithelial cells, enterocytes of the small and large intestine, and syncytiotrophoblasts of the placenta [<xref rid="cts70136-bib-0041" ref-type="bibr">41</xref>]. No effect on HD&#x02010;MTX clearance of the <italic toggle="yes">ABCC2</italic> rs717620 variant was found in our study population, suggesting that HEM toxicity was not related to excessive MTX systemic exposure, but rather to an accumulation of toxic levels of MTX in hematopoietic cells. Thiopurines are not substrate for MRP2 [<xref rid="cts70136-bib-0042" ref-type="bibr">42</xref>]; thus, the increased HEM toxicity observed for <italic toggle="yes">ABCC2</italic> rs717620 carriers is not likely related to accumulation of concomitant MP metabolites in hematopoietic stem cells. Conflicting results on the role of <italic toggle="yes">ABCC2</italic> rs717620 in MTX&#x02010;PK are reported in the literature, as reviewed by Taylor et&#x000a0;al. [<xref rid="cts70136-bib-0043" ref-type="bibr">43</xref>], likely because there is no linear correlation between the &#x02212;24T allele and the transporter functional expression. In <italic toggle="yes">in&#x000a0;vitro</italic> report gene assays, the &#x02212;24T allele was associated with both increased and decreased promoter function [<xref rid="cts70136-bib-0044" ref-type="bibr">44</xref>, <xref rid="cts70136-bib-0045" ref-type="bibr">45</xref>]; <italic toggle="yes">in&#x000a0;vivo</italic>, <italic toggle="yes">ABCC2</italic> rs717620 was reported in linkage disequilibrium (LD) with other <italic toggle="yes">ABCC2</italic> coding SNPs with uncertain impact on the efflux pump (i.e., rs2273697 (1249G&#x0003e;A, p.Val417Ile, <italic toggle="yes">D</italic>&#x02032;&#x02009;=&#x02009;0.694) and rs3740066 (c.3972C&#x0003e;T, p.Ile1324=, <italic toggle="yes">D</italic>&#x02032;&#x02009;=&#x02009;0.699)) [<xref rid="cts70136-bib-0046" ref-type="bibr">46</xref>]. Interestingly, <italic toggle="yes">ABCC2</italic> haplotype (&#x02212;24T, 1249G, 3972T) was associated with imatinib resistance in chronic myeloid leukemia patients, suggesting a lower expression of MRP2 protein and reduced transport activity in haplotype carriers [<xref rid="cts70136-bib-0047" ref-type="bibr">47</xref>]. The association between <italic toggle="yes">ABCC2</italic> rs717620 and HD&#x02010;MTX adverse effects deserved further validation studies, and it is worth performing a deeper genetic characterization of <italic toggle="yes">ABCC2</italic> gene and its promoter in ALL patients.</p><p>Our results showed a protective role of the rs4149056 C variant allele toward relapse. To the best of our knowledge, this is the first study demonstrating an association between rs4149056 SNP in the <italic toggle="yes">SLCO1B1</italic> gene and relapse risk in a Caucasian population of pediatric ALL patients treated according to the AIEOP&#x02010;BFM ALL guidelines. GWAS studies conducted on ALL pediatric patients identified SNPs in the <italic toggle="yes">SLCO1B1</italic> gene, encoding for the OAT1B1 MTX&#x02010;influx transporter and localized in the sinusoidal membrane of hepatocytes, as the major genetic marker of HD&#x02010;MTX pharmacokinetic variability [<xref rid="cts70136-bib-0015" ref-type="bibr">15</xref>, <xref rid="cts70136-bib-0048" ref-type="bibr">48</xref>]. Contribution of rare damaging nonsynonymous variants in <italic toggle="yes">SLCO1B1</italic> was also demonstrated [<xref rid="cts70136-bib-0015" ref-type="bibr">15</xref>]. Moreover, a mouse model using a knockout (KO) of the murine ortholog, <italic toggle="yes">Slco1b2</italic>, confirmed a compromised transport of MTX into hepatocytes and a decreased drug clearance [<xref rid="cts70136-bib-0049" ref-type="bibr">49</xref>]. The association between rs4149056 and PK parameters, although replicated in many ALL patients' cohorts [<xref rid="cts70136-bib-0037" ref-type="bibr">37</xref>, <xref rid="cts70136-bib-0050" ref-type="bibr">50</xref>] did not emerge in our study population of mainly Caucasian patients likely because of different genetic backgrounds, lifestyles, or treatment protocol. Previous studies on Saint Jude Children's Research Hospital trials associated the rs4149056 minor C allele to a decreased risk of MTX&#x02010;induced gastrointestinal complications in ALL patients, suggesting the contribution of the SNP as limiting for the biliary excretion of the drug into the intestine [<xref rid="cts70136-bib-0048" ref-type="bibr">48</xref>]. Again, controversial results on the impact of this genetic variant on other MTX&#x02010;related toxicities are reported in the literature [<xref rid="cts70136-bib-0051" ref-type="bibr">51</xref>] and were not evident in our study cohort. Discrepancy among results is probably due to difference in ethnicity of study populations, protocol treatments, and cohort size considered. We cannot rule out the hypothesis that the genetic contribution of rs4149056 on relapse is affecting the prolonged systemic exposure of MTX during maintenance rather than during consolidation. We reasoned that variability in the minor biliary excretion route of MTX (accounting for around 10%&#x02013;30% of MTX clearance) becomes somehow more important when hepatic metabolic enzymes (i.e., aldehyde oxidase generating inactive 7&#x02010;hydroxymethotrexate) and hepatic and renal transporters are not saturated by the drug, as it is likely to happen after low doses of MTX.</p><p>This study is an initial explorative retrospective study that focus on a limited number of SNPs in the MTX transport pathway. In particular, the study did not include the characterization of MTHFR SNPs rs1801133, which could be a limitation, especially when interpreting the association with outcome data. Future research could involve a more comprehensive characterization of genetic contributions to HD&#x02010;MTX pharmacokinetics using a GWAS approach. Moreover, in future studies, the current PK model could be further refined by incorporating important variables such as patients' kidney and liver function, age, and certain genetic variants. In conclusion, these data highlighted the importance of variants in drug transporters genes on HD&#x02010;MTX disposition in the AIEOP&#x02010;BFM ALL 2009 protocol consolidation phase, and their putative role as predictive markers of outcome. Age and <italic toggle="yes">ABCC4</italic> SNP rs7317112 affect HD&#x02010;MTX PK parameters, <italic toggle="yes">ABCC2</italic> SNP rs717620 could play a role as predictive marker of HD&#x02010;MTX&#x02010;induced HEM in consolidation and <italic toggle="yes">SLCO1B1</italic> SNP rs4149056 as predictive marker of relapse, if validated in additional AIEOP&#x02010;BFM cohorts. Further prospective studies will be required for the clinical application in particular of <italic toggle="yes">ABCC2</italic> SNP rs717620.</p></sec><sec id="cts70136-sec-0016"><title>Author Contributions</title><p>R.F., S.B., and G.Z. wrote the manuscript. R.F., G.S., G.D., and M.R. designed the research. R.F., S.B., G.Z., V.K., M.R., A.C., L.R.B., E.B., F.L., L.V., N.B., F.F., D.S., and M.G.V. performed the research. R.F., S.B., G.Z., and G.S. analyzed the data.</p></sec><sec sec-type="COI-statement" id="cts70136-sec-0019"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cts70136-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="CTS-18-e70136-s001.docx"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="cts70136-sec-0018"><title>Data Availability Statement</title><p>The original contributions presented in this manuscript are included in the article. Further inquiries can be directed to the corresponding author.</p></sec><ref-list content-type="cited-references" id="cts70136-bibl-0001"><title>References</title><ref id="cts70136-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cts70136-cit-0001">
<string-name>
<given-names>H.</given-names>
<surname>Inaba</surname>
</string-name> and <string-name>
<given-names>C. G.</given-names>
<surname>Mullighan</surname>
</string-name>, &#x0201c;<article-title>Pediatric Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Haematologica</source>
<volume>105</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>2524</fpage>&#x02013;<lpage>2539</lpage>, <pub-id pub-id-type="doi">10.3324/haematol.2020.247031</pub-id>.<pub-id pub-id-type="pmid">33054110</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cts70136-cit-0002">
<string-name>
<given-names>H.</given-names>
<surname>Abdullah&#x02010;Koolmees</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>van Keulen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Nijenhuis</surname>
</string-name>, and <string-name>
<given-names>V. H. M.</given-names>
<surname>Deneer</surname>
</string-name>, &#x0201c;<article-title>Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines</article-title>,&#x0201d; <source>Frontiers in Pharmacology</source>
<volume>11</volume> (<year>2020</year>): <elocation-id>595219</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphar.2020.595219</pub-id>.<pub-id pub-id-type="pmid">33568995</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cts70136-cit-0003">
<string-name>
<given-names>W. E.</given-names>
<surname>Evans</surname>
</string-name>, <string-name>
<given-names>M. V.</given-names>
<surname>Relling</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Boyett</surname>
</string-name>, and <string-name>
<given-names>C. H.</given-names>
<surname>Pui</surname>
</string-name>, &#x0201c;<article-title>Does Pharmacokinetic Variability Influence the Efficacy of High&#x02010;Dose Methotrexate for the Treatment of Children With Acute Lymphoblastic Leukemia: What Can We Learn From Small Studies?</article-title>,&#x0201d; <source>Leukemia Research</source>
<volume>21</volume>, no. <issue>5</issue> (<year>1997</year>): <fpage>435</fpage>&#x02013;<lpage>437</lpage>, <pub-id pub-id-type="doi">10.1016/s0145-2126(96)00128-2</pub-id>.<pub-id pub-id-type="pmid">9225072</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cts70136-cit-0004">
<string-name>
<given-names>R.</given-names>
<surname>Ramalingam</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Kaur</surname>
</string-name>, <string-name>
<given-names>J. X.</given-names>
<surname>Scott</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Evaluation of Cytogenetic and Molecular Markers With MTX&#x02010;Mediated Toxicity in Pediatric Acute Lymphoblastic Leukemia Patients</article-title>,&#x0201d; <source>Cancer Chemotherapy and Pharmacology</source>
<volume>89</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>393</fpage>&#x02013;<lpage>400</lpage>, <pub-id pub-id-type="doi">10.1007/s00280-022-04405-7</pub-id>.<pub-id pub-id-type="pmid">35157101</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cts70136-cit-0005">
<string-name>
<given-names>Y. G.</given-names>
<surname>Assaraf</surname>
</string-name>, &#x0201c;<article-title>The Role of Multidrug Resistance Efflux Transporters in Antifolate Resistance and Folate Homeostasis</article-title>,&#x0201d; <source>Drug Resistance Updates</source>
<volume>9</volume>, no. <issue>4&#x02013;5</issue> (<year>2006</year>): <fpage>227</fpage>&#x02013;<lpage>246</lpage>, <pub-id pub-id-type="doi">10.1016/j.drup.2006.09.001</pub-id>.<pub-id pub-id-type="pmid">17092765</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cts70136-cit-0006">
<string-name>
<given-names>J.</given-names>
<surname>K&#x000f6;nig</surname>
</string-name>, <string-name>
<given-names>A. T.</given-names>
<surname>Nies</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Cui</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Leier</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Keppler</surname>
</string-name>, &#x0201c;<article-title>Conjugate Export Pumps of the Multidrug Resistance Protein (MRP) Family: Localization, Substrate Specificity, and MRP2&#x02010;Mediated Drug Resistance</article-title>,&#x0201d; <source>Biochimica et Biophysica Acta</source>
<volume>1461</volume>, no. <issue>2</issue> (<year>1999</year>): <fpage>377</fpage>&#x02013;<lpage>394</lpage>, <pub-id pub-id-type="doi">10.1016/s0005-2736(99)00169-8</pub-id>.<pub-id pub-id-type="pmid">10581368</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cts70136-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>Basit</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Radi</surname>
</string-name>, <string-name>
<given-names>V. S.</given-names>
<surname>Vaidya</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Karasu</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Prasad</surname>
</string-name>, &#x0201c;<article-title>Kidney Cortical Transporter Expression Across Species Using Quantitative Proteomics</article-title>,&#x0201d; <source>Drug Metabolism and Disposition</source>
<volume>47</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>802</fpage>&#x02013;<lpage>808</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.119.086579</pub-id>.<pub-id pub-id-type="pmid">31123036</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cts70136-cit-0008">
<string-name>
<given-names>Y.</given-names>
<surname>Toyoda</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Hagiya</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Adachi</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Hoshijima</surname>
</string-name>, <string-name>
<given-names>M. T.</given-names>
<surname>Kuo</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Ishikawa</surname>
</string-name>, &#x0201c;<article-title>MRP Class of Human ATP Binding Cassette (ABC) Transporters: Historical Background and New Research Directions</article-title>,&#x0201d; <source>Xenobiotica</source>
<volume>38</volume>, no. <issue>7&#x02013;8</issue> (<year>2008</year>): <fpage>833</fpage>&#x02013;<lpage>862</lpage>, <pub-id pub-id-type="doi">10.1080/00498250701883514</pub-id>.<pub-id pub-id-type="pmid">18668432</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cts70136-cit-0009">
<string-name>
<given-names>P.</given-names>
<surname>Ko&#x0017a;mi&#x00144;ski</surname>
</string-name>, <string-name>
<given-names>P. K.</given-names>
<surname>Halik</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Chesori</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Gniazdowska</surname>
</string-name>, &#x0201c;<article-title>Overview of Dual&#x02010;Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume>, no. <issue>10</issue> (<year>2020</year>): <elocation-id>3483</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms21103483</pub-id>.<pub-id pub-id-type="pmid">32423175</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cts70136-cit-0010">
<string-name>
<given-names>S. C.</given-names>
<surname>Howard</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>McCormick</surname>
</string-name>, <string-name>
<given-names>C. H.</given-names>
<surname>Pui</surname>
</string-name>, <string-name>
<given-names>R. K.</given-names>
<surname>Buddington</surname>
</string-name>, and <string-name>
<given-names>R. D.</given-names>
<surname>Harvey</surname>
</string-name>, &#x0201c;<article-title>Preventing and Managing Toxicities of High&#x02010;Dose Methotrexate</article-title>,&#x0201d; <source>Oncologist</source>
<volume>21</volume>, no. <issue>12</issue> (<year>2016</year>): <fpage>1471</fpage>&#x02013;<lpage>1482</lpage>, <pub-id pub-id-type="doi">10.1634/theoncologist.2015-0164</pub-id>.<pub-id pub-id-type="pmid">27496039</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cts70136-cit-0011">
<string-name>
<given-names>B. C.</given-names>
<surname>Widemann</surname>
</string-name> and <string-name>
<given-names>P. C.</given-names>
<surname>Adamson</surname>
</string-name>, &#x0201c;<article-title>Understanding and Managing Methotrexate Nephrotoxicity</article-title>,&#x0201d; <source>Oncologist</source>
<volume>11</volume>, no. <issue>6</issue> (<year>2006</year>): <fpage>694</fpage>&#x02013;<lpage>703</lpage>, <pub-id pub-id-type="doi">10.1634/theoncologist.11-6-694</pub-id>.<pub-id pub-id-type="pmid">16794248</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cts70136-cit-0012">
<string-name>
<given-names>D.</given-names>
<surname>Bhojwani</surname>
</string-name>, <string-name>
<given-names>N. D.</given-names>
<surname>Sabin</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Pei</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methotrexate&#x02010;Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>32</volume>, no. <issue>9</issue> (<year>2014</year>): <fpage>949</fpage>&#x02013;<lpage>959</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2013.53.0808</pub-id>.<pub-id pub-id-type="pmid">24550419</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cts70136-cit-0013">
<string-name>
<given-names>A. N.</given-names>
<surname>Malaviya</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sharma</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Agarwal</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kapoor</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Garg</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Sawhney</surname>
</string-name>, &#x0201c;<article-title>Low&#x02010;Dose and High&#x02010;Dose Methotrexate Are Two Different Drugs in Practical Terms</article-title>,&#x0201d; <source>International Journal of Rheumatic Diseases</source>
<volume>13</volume>, no. <issue>4</issue> (<year>2010</year>): <fpage>288</fpage>&#x02013;<lpage>293</lpage>, <pub-id pub-id-type="doi">10.1111/j.1756-185X.2010.01564.x</pub-id>.<pub-id pub-id-type="pmid">21199463</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cts70136-cit-0014">
<string-name>
<given-names>Y. H.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>S. S.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methotrexate Disposition in Pediatric Patients With Acute Lymphoblastic Leukemia: What Have we Learnt From the Genetic Variants of Drug Transporters</article-title>,&#x0201d; <source>Current Pharmaceutical Design</source>
<volume>25</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>627</fpage>&#x02013;<lpage>634</lpage>, <pub-id pub-id-type="doi">10.2174/1381612825666190329141003</pub-id>.<pub-id pub-id-type="pmid">30931851</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cts70136-cit-0015">
<string-name>
<given-names>L. B.</given-names>
<surname>Ramsey</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Panetta</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Smith</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genome&#x02010;Wide Study of Methotrexate Clearance Replicates SLCO1B1</article-title>,&#x0201d; <source>Blood</source>
<volume>121</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>898</fpage>&#x02013;<lpage>904</lpage>, <pub-id pub-id-type="doi">10.1182/blood-2012-08-452839</pub-id>.<pub-id pub-id-type="pmid">23233662</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cts70136-cit-0016">
<string-name>
<given-names>R.</given-names>
<surname>Franca</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Zudeh</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lucaf&#x000f2;</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Rabusin</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Decorti</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Stocco</surname>
</string-name>, &#x0201c;<article-title>Genome Wide Association Studies for Treatment&#x02010;Related Adverse Effects of Pediatric Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>WIREs Mechanisms of Disease</source>
<volume>13</volume>, no. <issue>3</issue> (<year>2021</year>): <elocation-id>e1509</elocation-id>, <pub-id pub-id-type="doi">10.1002/wsbm.1509</pub-id>.<pub-id pub-id-type="pmid">33016644</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cts70136-cit-0017">
<string-name>
<given-names>M.</given-names>
<surname>Kroll</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kaupat&#x02010;Bleckmann</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>M&#x000f6;rickel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methotrexate&#x02010;Associated Toxicity in Children With Down Syndrome and Acute Lymphoblastic Leukemia During Consolidation Therapy With High Dose Methotrexate According to ALL&#x02010;BFM Treatment Regimen</article-title>,&#x0201d; <source>Haematologica</source>
<volume>105</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>1013</fpage>&#x02013;<lpage>1020</lpage>, <pub-id pub-id-type="doi">10.3324/haematol.2019.224774</pub-id>.<pub-id pub-id-type="pmid">31371414</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cts70136-cit-0018">
<string-name>
<given-names>J. L.</given-names>
<surname>Pauley</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Panetta</surname>
</string-name>, <string-name>
<given-names>K. R.</given-names>
<surname>Crews</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Between&#x02010;Course Targeting of Methotrexate Exposure Using Pharmacokinetically Guided Dosage Adjustments</article-title>,&#x0201d; <source>Cancer Chemotherapy and Pharmacology</source>
<volume>72</volume>, no. <issue>2</issue> (<year>2013</year>): <fpage>369</fpage>&#x02013;<lpage>378</lpage>, <pub-id pub-id-type="doi">10.1007/s00280-013-2206-x</pub-id>.<pub-id pub-id-type="pmid">23760811</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cts70136-cit-0019">
<string-name>
<given-names>P.</given-names>
<surname>Pisani</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Buzzoni</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Crocetti</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Italian Cancer Figures, Report 2012: Cancer in Children and Adolescents</article-title>,&#x0201d; <source>Epidemiologia e Prevenzione</source>
<volume>37</volume>, no. <issue>1 Suppl 1</issue> (<year>2013</year>): <fpage>1</fpage>&#x02013;<lpage>225</lpage>.</mixed-citation></ref><ref id="cts70136-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cts70136-cit-0020">
<string-name>
<given-names>D.</given-names>
<surname>Ferrari</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Stefanucci</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ciofi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Analysis of the Timing of Puberty in a Recent Cohort of Italian Girls: Evidence for Earlier Onset Compared to Previous Studies</article-title>,&#x0201d; <source>Journal of Pediatric and Adolescent Gynecology</source>
<volume>35</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>23</fpage>&#x02013;<lpage>29</lpage>, <pub-id pub-id-type="doi">10.1016/j.jpag.2021.06.007</pub-id>.<pub-id pub-id-type="pmid">34166823</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cts70136-cit-0021">
<string-name>
<given-names>S. E.</given-names>
<surname>Karol</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Pei</surname>
</string-name>, <string-name>
<given-names>C. A.</given-names>
<surname>Smith</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Comprehensive Analysis of Dose Intensity of Acute Lymphoblastic Leukemia Chemotherapy</article-title>,&#x0201d; <source>Haematologica</source>
<volume>107</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>371</fpage>&#x02013;<lpage>380</lpage>, <pub-id pub-id-type="doi">10.3324/haematol.2021.278411</pub-id>.<pub-id pub-id-type="pmid">34196166</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cts70136-cit-0022">
<string-name>
<given-names>Y.</given-names>
<surname>Tan</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Kong</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Relationship Between Methylenetetrahydrofolate Reductase Gene Polymorphisms and Methotrexate Drug Metabolism and Toxicity</article-title>,&#x0201d; <source>Translational Pediatrics</source>
<volume>12</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>31</fpage>&#x02013;<lpage>45</lpage>, <pub-id pub-id-type="doi">10.21037/tp-22-671</pub-id>.<pub-id pub-id-type="pmid">36798930</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cts70136-cit-0023">
<string-name>
<given-names>Z.</given-names>
<surname>Song</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Role of Genetic Polymorphisms in High&#x02010;Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Frontiers in Pharmacology</source>
<volume>12</volume> (<year>2021</year>): <elocation-id>757464</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphar.2021.757464</pub-id>.<pub-id pub-id-type="pmid">34744734</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cts70136-cit-0024">
<string-name>
<given-names>P.</given-names>
<surname>Bohanec Grabar</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Leandro&#x02010;Garc&#x000ed;a</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Inglada&#x02010;P&#x000e9;rez</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Logar</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Rodr&#x000ed;guez&#x02010;Antona</surname>
</string-name>, and <string-name>
<given-names>V.</given-names>
<surname>Dol&#x0017e;an</surname>
</string-name>, &#x0201c;<article-title>Genetic Variation in the SLC19A1 Gene and Methotrexate Toxicity in Rheumatoid Arthritis Patients</article-title>,&#x0201d; <source>Pharmacogenomics</source>
<volume>13</volume>, no. <issue>14</issue> (<year>2012</year>): <fpage>1583</fpage>&#x02013;<lpage>1594</lpage>, <pub-id pub-id-type="doi">10.2217/pgs.12.150</pub-id>.<pub-id pub-id-type="pmid">23148635</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cts70136-cit-0025">
<string-name>
<given-names>M. A.</given-names>
<surname>Alshabeeb</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Alyabsi</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Aziz</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Abohelaika</surname>
</string-name>, &#x0201c;<article-title>Pharmacogenes That Demonstrate High Association Evidence According to CPIC, DPWG, and PharmGKB</article-title>,&#x0201d; <source>Front Med (Lausanne)</source>
<volume>9</volume> (<year>2022</year>): <elocation-id>1001876</elocation-id>, <pub-id pub-id-type="doi">10.3389/fmed.2022.1001876</pub-id>.<pub-id pub-id-type="pmid">36388934</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cts70136-cit-0026">
<string-name>
<given-names>R.</given-names>
<surname>Franca</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Zudeh</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Pagarin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Pharmacogenetics of Thiopurines</article-title>,&#x0201d; <source>Cancer Drug Resistance</source>
<volume>2</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>256</fpage>&#x02013;<lpage>270</lpage>, <pub-id pub-id-type="doi">10.20517/cdr.2019.004</pub-id>.<pub-id pub-id-type="pmid">35582727</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cts70136-cit-0027">
<string-name>
<given-names>G.</given-names>
<surname>Zudeh</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Franca</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lucaf&#x000f2;</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>As a Modulator of Autophagy and Mercaptopurine Cytotoxicity: Mechanisms in Lymphoid and Intestinal Cells</article-title>,&#x0201d; <source>Life Science Alliance</source>
<volume>6</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>610</elocation-id>, <pub-id pub-id-type="doi">10.26508/lsa.202201610</pub-id>.</mixed-citation></ref><ref id="cts70136-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cts70136-cit-0028">
<string-name>
<given-names>C.</given-names>
<surname>Rizzari</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Lanvers&#x02010;Kaminsky</surname>
</string-name>, <string-name>
<given-names>M. G.</given-names>
<surname>Valsecchi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Asparagine Levels in the Cerebrospinal Fluid of Children With Acute Lymphoblastic Leukemia Treated With Pegylated&#x02010;Asparaginase in the Induction Phase of the AIEOP&#x02010;BFM ALL 2009 Study</article-title>,&#x0201d; <source>Haematologica</source>
<volume>104</volume>, no. <issue>9</issue> (<year>2019</year>): <fpage>1812</fpage>&#x02013;<lpage>1821</lpage>, <pub-id pub-id-type="doi">10.3324/haematol.2018.206433</pub-id>.<pub-id pub-id-type="pmid">30705097</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cts70136-cit-0029">
<string-name>
<given-names>G.</given-names>
<surname>Cario</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Leoni</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Conter</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Relapses and Treatment&#x02010;Related Events Contributed Equally to Poor Prognosis in Children With ABL&#x02010;Class Fusion Positive B&#x02010;Cell Acute Lymphoblastic Leukemia Treated According to AIEOP&#x02010;BFM Protocols</article-title>,&#x0201d; <source>Haematologica</source>
<volume>105</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>1887</fpage>&#x02013;<lpage>1894</lpage>, <pub-id pub-id-type="doi">10.3324/haematol.2019.231720</pub-id>.<pub-id pub-id-type="pmid">31601692</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cts70136-cit-0030">
<string-name>
<given-names>M. C.</given-names>
<surname>Zobeck</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Bernhardt</surname>
</string-name>, <string-name>
<given-names>K. Y.</given-names>
<surname>Kamdar</surname>
</string-name>, <string-name>
<given-names>K. R.</given-names>
<surname>Rabin</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Lupo</surname>
</string-name>, and <string-name>
<given-names>M. E.</given-names>
<surname>Scheurer</surname>
</string-name>, &#x0201c;<article-title>Novel Risk Factors for Glucarpidase Use in Pediatric Acute Lymphoblastic Leukemia: Hispanic Ethnicity, Age, and the ABCC4 Gene</article-title>,&#x0201d; <source>Pediatric Blood &#x00026; Cancer</source>
<volume>68</volume>, no. <issue>8</issue> (<year>2021</year>): <elocation-id>e29036</elocation-id>, <pub-id pub-id-type="doi">10.1002/pbc.29036</pub-id>.<pub-id pub-id-type="pmid">33788417</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cts70136-cit-0031">
<string-name>
<given-names>A.</given-names>
<surname>Freire&#x02010;Aradas</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Phillips</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gir&#x000f3;n&#x02010;Santamar&#x000ed;a</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Tracking Age&#x02010;Correlated DNA Methylation Markers in the Young</article-title>,&#x0201d; <source>Forensic Science International: Genetics</source>
<volume>36</volume> (<year>2018</year>): <fpage>50</fpage>&#x02013;<lpage>59</lpage>, <pub-id pub-id-type="doi">10.1016/j.fsigen.2018.06.011</pub-id>.<pub-id pub-id-type="pmid">29933125</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cts70136-cit-0032">
<string-name>
<given-names>E.</given-names>
<surname>Arrigoni</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Galimberti</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Petrini</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Danesi</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Di Paolo</surname>
</string-name>, &#x0201c;<article-title>ATP&#x02010;Binding Cassette Transmembrane Transporters and Their Epigenetic Control in Cancer: An Overview</article-title>,&#x0201d; <source>Expert Opinion on Drug Metabolism &#x00026; Toxicology</source>
<volume>12</volume>, no. <issue>12</issue> (<year>2016</year>): <fpage>1419</fpage>&#x02013;<lpage>1432</lpage>, <pub-id pub-id-type="doi">10.1080/17425255.2016.1215423</pub-id>.<pub-id pub-id-type="pmid">27459275</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cts70136-cit-0033">
<string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methylation Level of CpG Islands in GGH Gene Promoter in Pediatric Acute Leukemia</article-title>,&#x0201d; <source>PLoS One</source>
<volume>12</volume>, no. <issue>3</issue> (<year>2017</year>): <elocation-id>e0173472</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0173472</pub-id>.<pub-id pub-id-type="pmid">28278270</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cts70136-cit-0034">
<string-name>
<given-names>S. M.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X. Y.</given-names>
<surname>Kong</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>L. L.</given-names>
<surname>Sun</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Yan</surname>
</string-name>, &#x0201c;<article-title>Association of GGH Promoter Methylation Levels With Methotrexate Concentrations in Chinese Children With Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Pharmacotherapy</source>
<volume>40</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>614</fpage>&#x02013;<lpage>622</lpage>, <pub-id pub-id-type="doi">10.1002/phar.2430</pub-id>.<pub-id pub-id-type="pmid">32476160</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cts70136-cit-0035">
<string-name>
<given-names>B. J.</given-names>
<surname>Anderson</surname>
</string-name> and <string-name>
<given-names>N. H.</given-names>
<surname>Holford</surname>
</string-name>, &#x0201c;<article-title>Understanding Dosing: Children Are Small Adults, Neonates Are Immature Children</article-title>,&#x0201d; <source>Archives of Disease in Childhood</source>
<volume>98</volume>, no. <issue>9</issue> (<year>2013</year>): <fpage>737</fpage>&#x02013;<lpage>744</lpage>, <pub-id pub-id-type="doi">10.1136/archdischild-2013-303720</pub-id>.<pub-id pub-id-type="pmid">23832061</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cts70136-cit-0036">
<string-name>
<given-names>M. A.</given-names>
<surname>den Hoed</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Lopez&#x02010;Lopez</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>te Winkel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genetic and Metabolic Determinants of Methotrexate&#x02010;Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Pharmacogenomics Journal</source>
<volume>15</volume>, no. <issue>3</issue> (<year>2015</year>): <fpage>248</fpage>&#x02013;<lpage>254</lpage>, <pub-id pub-id-type="doi">10.1038/tpj.2014.63</pub-id>.<pub-id pub-id-type="pmid">25348617</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cts70136-cit-0037">
<string-name>
<given-names>Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Yin</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Sheng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Association of ABCC2 &#x02010;24C&#x0003e;T Polymorphism With High&#x02010;Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>PLoS One</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2014</year>): <elocation-id>e82681</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0082681</pub-id>.<pub-id pub-id-type="pmid">24404132</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cts70136-cit-0038">
<string-name>
<given-names>N. K.</given-names>
<surname>Zgheib</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Akra&#x02010;Ismail</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Aridi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genetic Polymorphisms in Candidate Genes Predict Increased Toxicity With Methotrexate Therapy in Lebanese Children With Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Pharmacogenetics and Genomics</source>
<volume>24</volume>, no. <issue>8</issue> (<year>2014</year>): <fpage>387</fpage>&#x02013;<lpage>396</lpage>, <pub-id pub-id-type="doi">10.1097/FPC.0000000000000069</pub-id>.<pub-id pub-id-type="pmid">25007187</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cts70136-cit-0039">
<string-name>
<given-names>R. H.</given-names>
<surname>Razali</surname>
</string-name>, <string-name>
<given-names>M. N. F.</given-names>
<surname>Noorizhab</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Jamari</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Association of <italic toggle="yes">ABCC2</italic> With Levels and Toxicity of Methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL)</article-title>,&#x0201d; <source>Pediatric Hematology and Oncology</source>
<volume>37</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>185</fpage>&#x02013;<lpage>197</lpage>, <pub-id pub-id-type="doi">10.1080/08880018.2019.1705949</pub-id>.<pub-id pub-id-type="pmid">31870219</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cts70136-cit-0040">
<string-name>
<given-names>T.</given-names>
<surname>Rau</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Erney</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>G&#x000f6;res</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Eschenhagen</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Beck</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Langer</surname>
</string-name>, &#x0201c;<article-title>High&#x02010;Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Impact of ABCC2 Polymorphisms on Plasma Concentrations</article-title>,&#x0201d; <source>Clinical Pharmacology and Therapeutics</source>
<volume>80</volume>, no. <issue>5</issue> (<year>2006</year>): <fpage>468</fpage>&#x02013;<lpage>476</lpage>, <pub-id pub-id-type="doi">10.1016/j.clpt.2006.08.012</pub-id>.<pub-id pub-id-type="pmid">17112803</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cts70136-cit-0041">
<string-name>
<given-names>K.</given-names>
<surname>Jemnitz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Heredi&#x02010;Szabo</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Janossy</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Ioja</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Vereczkey</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Krajcsi</surname>
</string-name>, &#x0201c;<article-title>ABCC2/Abcc2: A Multispecific Transporter With Dominant Excretory Functions</article-title>,&#x0201d; <source>Drug Metabolism Reviews</source>
<volume>42</volume>, no. <issue>3</issue> (<year>2010</year>): <fpage>402</fpage>&#x02013;<lpage>436</lpage>, <pub-id pub-id-type="doi">10.3109/03602530903491741</pub-id>.<pub-id pub-id-type="pmid">20082599</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cts70136-cit-0042">
<string-name>
<given-names>A. A.</given-names>
<surname>El&#x02010;Sheikh</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Greupink</surname>
</string-name>, <string-name>
<given-names>H. M.</given-names>
<surname>Wortelboer</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interaction of Immunosuppressive Drugs With Human Organic Anion Transporter (OAT) 1 and OAT3, and Multidrug Resistance&#x02010;Associated Protein (MRP) 2 and MRP4</article-title>,&#x0201d; <source>Translational Research</source>
<volume>162</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>398</fpage>&#x02013;<lpage>409</lpage>, <pub-id pub-id-type="doi">10.1016/j.trsl.2013.08.003</pub-id>.<pub-id pub-id-type="pmid">24036158</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cts70136-cit-0043">
<string-name>
<given-names>Z. L.</given-names>
<surname>Taylor</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Vang</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Lopez&#x02010;Lopez</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Oosterom</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Mikkelsen</surname>
</string-name>, and <string-name>
<given-names>L. B.</given-names>
<surname>Ramsey</surname>
</string-name>, &#x0201c;<article-title>Systematic Review of Pharmacogenetic Factors That Influence High&#x02010;Dose Methotrexate Pharmacokinetics in Pediatric Malignancies</article-title>,&#x0201d; <source>Cancers (Basel)</source>
<volume>13</volume>, no. <issue>11</issue> (<year>2021</year>): <elocation-id>2837</elocation-id>, <pub-id pub-id-type="doi">10.3390/cancers13112837</pub-id>.<pub-id pub-id-type="pmid">34200242</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cts70136-cit-0044">
<string-name>
<given-names>T. D.</given-names>
<surname>Nguyen</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Markova</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Functional Characterization of ABCC2 Promoter Polymorphisms and Allele&#x02010;Specific Expression</article-title>,&#x0201d; <source>Pharmacogenomics Journal</source>
<volume>13</volume>, no. <issue>5</issue> (<year>2013</year>): <fpage>396</fpage>&#x02013;<lpage>402</lpage>, <pub-id pub-id-type="doi">10.1038/tpj.2012.20</pub-id>.<pub-id pub-id-type="pmid">22664480</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cts70136-cit-0045">
<string-name>
<given-names>S.</given-names>
<surname>Haenisch</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Zimmermann</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Dazert</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Influence of Polymorphisms of ABCB1 and ABCC2 on mRNA and Protein Expression in Normal and Cancerous Kidney Cortex</article-title>,&#x0201d; <source>Pharmacogenomics Journal</source>
<volume>7</volume>, no. <issue>1</issue> (<year>2007</year>): <fpage>56</fpage>&#x02013;<lpage>65</lpage>, <pub-id pub-id-type="doi">10.1038/sj.tpj.6500403</pub-id>.<pub-id pub-id-type="pmid">16788565</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cts70136-cit-0046">
<string-name>
<given-names>J.</given-names>
<surname>Qu</surname>
</string-name>, <string-name>
<given-names>B. T.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Yin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>ABCC2 Polymorphisms and Haplotype Are Associated With Drug Resistance in Chinese Epileptic Patients</article-title>,&#x0201d; <source>CNS Neuroscience &#x00026; Therapeutics</source>
<volume>18</volume>, no. <issue>8</issue> (<year>2012</year>): <fpage>647</fpage>&#x02013;<lpage>651</lpage>, <pub-id pub-id-type="doi">10.1111/j.1755-5949.2012.00336.x</pub-id>.<pub-id pub-id-type="pmid">22630058</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cts70136-cit-0047">
<string-name>
<given-names>A.</given-names>
<surname>Au</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Baba</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Azlan</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Norsa'adah</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Ankathil</surname>
</string-name>, &#x0201c;<article-title>Clinical Impact of ABCC1 and ABCC2 Genotypes and Haplotypes in Mediating Imatinib Resistance Among Chronic Myeloid Leukaemia Patients</article-title>,&#x0201d; <source>Journal of Clinical Pharmacy and Therapeutics</source>
<volume>39</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>685</fpage>&#x02013;<lpage>690</lpage>, <pub-id pub-id-type="doi">10.1111/jcpt.12197</pub-id>.<pub-id pub-id-type="pmid">25060527</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cts70136-cit-0048">
<string-name>
<given-names>L. R.</given-names>
<surname>Trevi&#x000f1;o</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Shimasaki</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>27</volume>, no. <issue>35</issue> (<year>2009</year>): <fpage>5972</fpage>&#x02013;<lpage>5978</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2008.20.4156</pub-id>.<pub-id pub-id-type="pmid">19901119</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cts70136-cit-0049">
<string-name>
<given-names>Z. L.</given-names>
<surname>Taylor</surname>
</string-name>, <string-name>
<given-names>L. E.</given-names>
<surname>Thompson</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Bear</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Mizuno</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Vinks</surname>
</string-name>, and <string-name>
<given-names>L. B.</given-names>
<surname>Ramsey</surname>
</string-name>, &#x0201c;<article-title>Toward Pharmacogenetic SLCO1B1&#x02010;Guided Dosing of Methotrexate in Arthritis Using a Murine Slco1b2 Knockout Model</article-title>,&#x0201d; <source>Clinical and Translational Science</source>
<volume>14</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>2267</fpage>&#x02013;<lpage>2277</lpage>, <pub-id pub-id-type="doi">10.1111/cts.13086</pub-id>.<pub-id pub-id-type="pmid">34121338</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cts70136-cit-0050">
<string-name>
<given-names>H.</given-names>
<surname>Fukushima</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Fukushima</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sakai</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Polymorphisms of MTHFR Associated With Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies</article-title>,&#x0201d; <source>Leukemia Research Treatment</source>
<volume>2013</volume> (<year>2013</year>): <elocation-id>238528</elocation-id>, <pub-id pub-id-type="doi">10.1155/2013/238528</pub-id>.<pub-id pub-id-type="pmid">24386571</pub-id>
</mixed-citation></ref><ref id="cts70136-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cts70136-cit-0051">
<string-name>
<given-names>Y.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhuang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genetic Factors Involved in Delayed Methotrexate Elimination in Children With Acute Lymphoblastic Leukemia</article-title>,&#x0201d; <source>Pediatric Blood &#x00026; Cancer</source>
<volume>68</volume>, no. <issue>5</issue> (<year>2021</year>): <elocation-id>e28858</elocation-id>, <pub-id pub-id-type="doi">10.1002/pbc.28858</pub-id>.<pub-id pub-id-type="pmid">33501733</pub-id>
</mixed-citation></ref></ref-list></back></article>